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ABSTRACT 
 
Gene therapy is a promising new treatment option for ischemic heart disease and 
peripheral arterial disease. Viral vectors are used to deliver therapeutic genes to ischemic 
tissue, and transduced cells begin to produce therapeutic proteins locally. Ischemia is a 
result of insufficient blood flow, and induction of blood vessel growth in the ischemic tissue 
is a potential treatment option for ischemic diseases. Vascular endothelial growth factors 
(VEGFs) regulate blood and lymphatic vessel growth both during development and as an 
endogenous response to ischemia. Viral delivery of VEGFs could therefore be used to 
treat ischemic diseases. 
Vascular endothelial growth factors mediate their effects via VEGF receptors 
(VEGFR-1-3) and their effects vary from angiogenic to lymphangiogenic responses. In this 
study we first compared these growth factors by adenovirally expressing them in a rabbit 
model of hind limb ischemia. VEGF-D∆N∆C was the most potent angiogenic factor and 
VEGF-Dfull produced the strongest lymphangiogenic response. Angiogenic factors VEGF-A 
and VEGF-D∆N∆C increased vascular permeability and edema as a side effect. VEGF-Cfull, 
VEGF-C156S and VEGF-Dfull only induced growth of lymphatic vessels. 
The effects of VEGFR-2 ligands VEGF-A and VEGF-D∆N∆C were studied in 
normoxic pig myocardium. Adenoviruses were injected intramyocardially via a NOGA® 
injection catheter. Both VEGF-A and VEGF-D∆N∆C induced angiogenesis in a dose-
dependent manner and increased perfusion as measured by contrast-enhanced 
ultrasound imaging. Both growth factors also increased plasma protein extravasation, and 
larger doses led to accumulation of pericardial effusion. 
VEGFR-1 ligands VEGF-A and PlGF induced angiogenesis both in skeletal 
muscle and myocardium via a VEGFR-2 dependent pathway, while VEGF-B induced 
blood vessel growth only in the myocardium. This tissue-specific angiogenic response was 
mediated via a new VEGFR-1 and Nrp-1 dependent pathway. VEGF-B also induced 
growth of collateral arteries in the infarction border zone and improved left ventricular 
ejection fraction. In addition, VEGF-B induced metabolic changes in the myocardial cells 
and inhibited apoptosis in the infarction border zone. 
As increased vascular permeability, edema and accumulation of pericardial 
effusion are serious side effects of angiogenic gene therapy, we also explored the 
possibility to alleviate edema by induction of lymphatic vessel growth. Combination gene 
therapy with VEGF-D∆N∆C and VEGF-Dfull increased angiogenesis but decreased vascular 
permeability by 60% as compared to VEGF-D∆N∆C monotherapy in rabbit skeletal muscles. 
In conclusion, adenoviral delivery of VEGFs is a potent tool to treat ischemia both 
in myocardium and peripheral muscles. VEGFs can also be used to alleviate the side 
effects of angiogenic gene therapy by induction of lymphatic vessel growth. 
 
National Library of Medicine Classification: WG 300, WG 104, QU 107, QW 165.5.A3 
Medical Subject Headings: Gene Therapy; Myocardial Ischemia; Peripheral Vascular 
Diseases; Angiogenesis Inducing Agents; Vascular Endothelial Growth Factors; 
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“By three methods we may learn wisdom: First, by reflection, which is noblest; second, by 
imitation, which is easiest; and third, by experience, which is the bitterest."  
Kung Fu-tse 
(ca. 551—478 BCE) 
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INTRODUCTION 
 
 Cardiovascular diseases are the leading cause of death in industrialized countries. 
Efficient primary prevention, early diagnosis and efficient treatment methods have 
increased the prevalence. Patients are older, and often have undergone several 
revascularization procedures. Conventional treatment methods are not suitable or feasible 
for all patients, and a growing number of patients fall into this “no option” category. 
Therapeutic angiogenesis, stimulation of blood vessel growth to salvage ischemic tissue 
was first proposed as a new treatment method for cardiovascular diseases over thirty 
years ago (Svet-Moldavsky and Chimishkyan, 1977). Discovery of a growth factor inducing 
blood vessel growth (angiogenesis) in tumors (VEGF) and development of viral gene 
transfer techniques enabled the first gene transfer experiment to ischemic myocardium in 
experimental animals in 1996 (Giordano et al., 1996) and the first adenoviral gene transfer 
to human myocardium in 1999 (Rosengart et al., 1999). 
 Despite the early optimism the development of therapeutic angiogenesis has been 
slow. Instead of being a simple angiogenic factor VEGFs have proven to be a large family 
of growth factors inducing various effects from blood and lymphatic vessel growth to 
metabolic effects, regulation of blood vessel permeability and inflammatory responses. It 
has become evident that development of a safe and efficient angiogenic therapy requires 
thorough knowledge of the biological function of these growth factors, localized and 
efficient gene transfer techniques and clinically applicable experiments in large animal 
models and finally a series of clinical phase I studies. 
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REVIEW OF THE LITERATURE 
 
GENE THERAPY 
 
 In gene therapy the treated tissue is stimulated to produce therapeutic agents 
locally. Most potential advantages of gene therapy are long term expression of the 
therapeutic agent and the possibility to target the treatment to the desired tissue (Ylä-
Herttuala and Alitalo, 2003). The therapeutic approach has to be designed to best suit the 
treated condition. The combination of viral vector, delivery method and choice of the 
therapeutic gene define where and how long the therapeutic protein is produced. While 
some diseases require a life long production of the drug, for some conditions weeks or 
months of production of the therapeutic agent is sufficient (Kay et al., 2001). 
Expression time is dependent on the vector used: vectors integrating into the host 
genome produce the therapeutic product for the lifespan of the transduced cell while some 
viruses only produce the transgene for a few weeks (Kay et al., 2001). Locality of the 
treatment depends on the delivery method, and the qualities of the vector carrying the 
transgene. The range of the cells transduced depends on the natural tropism of the virus 
used, but can be modified by several targeting methods. Modifications of the virus surface, 
selective promoters to limit the transgene expression to a desired cell type or targeting the 
transgene product itself have been used (Rots et al., 2003). The properties of the 
therapeutic protein, such as solubility, interactions with endogenous molecules and 
immunogenicity further shape the therapeutic response.   
Non-viral vectors 
 
 Non-viral vectors have been proposed to provide a safe method for gene transfer. 
In early experiments in mouse skeletal muscles, high transduction efficiency and 
transgene expression of several months were reported (Wolff et al., 1992). However, 
transduction efficiency was considerably lower in non-human primates (Jiao et al., 1992). 
Naked plasmids are easy to produce in high concentrations (Wolff and Budker, 2005), but 
due to lack of specific cell entry mechanisms, instability in extracellular milieu, tendency to 
be targeted to intracellular degradation pathways and lack of effective transport into the 
nucleus transduction efficiencies have been low in vivo (Lu et al., 2003). Although no 
severe side effects have been observed in clinical trials, transient fever has been observed 
after naked plasmid gene transfer (Hedman et al., 2003). Although considered a safe gene 
transfer method, widespread inflammation has been observed after intramuscular injection 
of naked plasmids in experimental animal models (McMahon et al., 1998) and possible 
formation of anti-DNA antibodies in autoimmune conditions (MacColl et al., 2001). Marked 
increases in transduction efficiency have been published by using ultrasound to 
permeabilize endothelial cells or by using cationic liposomes as carriers (Lawrie et al., 
2000).  
Adenoviral vectors 
 
 Adenoviral (Ad) vectors have high transduction efficiency and express the 
transgene for 1-2 weeks (Yang et al., 1994). Adenoviruses are capable of transducing 
both dividing and quiescent cells in a wide variety of tissues (Horwitz, 1996). Wild type 
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adenoviruses cause respiratory and gastrointestinal infections and myocarditis (Martin et 
al., 1994), and have tropism for liver but transduce a wide variety of cell types. The cell 
entry of most commonly used serotypes is mediated via coxsackie and adenovirus 
receptor (CAR, CD46) (Bergelson et al., 1997), and also heparin sulphate proteoglycans 
and integrins are involved in virus binding and internalization (Wickham et al., 1993; 
Dechecchi et al., 2001). Several targeting approaches have been used to increase 
transduction efficiency in treated tissues and to limit side effects, including modifications of 
the receptor binding sites on cell surface, antibody mediated targeting and tissue-specific 
promoters (Baker, 2004).  Adenovirus has a limited transgene capacity of approximately 
up to 8kb, but it can be produced in high titers (Kovesdi et al., 1997). Adenoviruses have 
been used for gene therapy for decades, and adenoviruses are the most commonly used 
vectors in gene therapy trials (http://www.wiley.co.uk/genetherapy/clinical/).  Adenoviruses 
trigger both innate and acquired immune responses, and production of neutralizing 
antibodies prevents repeated administration of the therapeutic agent (St George, 2003). 
This problem has been circumvented in animal models by the use of another adenoviral 
serotype for the second gene transfer (Parks et al., 1999). Most humans have naturally 
been exposed to the adenovirus serotypes used most commonly as gene transfer vectors 
(Horwitz, 1996), possibly preventing efficient transduction. Despite the immunologic 
reactions, only mild fever and a transient rise in liver transaminases has been observed in 
human trials, and a large number of clinical trials have been done without any serious 
adverse effects connected to the virus (Ylä-Herttuala et al., 2007).  
 
CARDIOVASCULAR SYSTEM 
Anatomy and function of the cardiovascular system 
 
 The cardiovascular system delivers oxygen and nutrients to tissues, provides a 
route for transport of chemical messengers throughout the body and is essential for 
immune defense and removal of waste products. The heart pumps blood to the systemic 
circulation and maintains a blood pressure sufficient to deliver blood throughout the body. 
The left ventricle pumps oxygenated blood to peripheral tissues and the right ventricle 
pumps oxygen poor blood to the lungs. Contraction of the heart, the systole, pushes blood 
out from the ventricle through the aortic valve, and blood flows into the heart during the 
relaxation of the heart muscle, the diastole. The amount of blood pumped out during each 
systole is expressed as stroke volume (Guyton and Hall, 2000). 
 The contraction of the individual cardiomyocytes has to be tightly controlled to 
achieve coordinated, rhythmic contraction of the heart. Specialized myocytes in the 
sinoatrial node initiate a wave of depolarization of the atrial cardiomyocytes which is 
further conducted to the ventricles via the atrioventricular node. Depolarization spreads to 
the ventricles via the fast-conducting atrioventricular bundle (bundle of His), which divides 
into the left and right bundle branches. Purkinje fibers, chords of specialized myocardial 
cells, spread the depolarization to contracting cardiomyocytes. Cardiomyocytes are tightly 
connected to the surrounding cells via gap junctions, electrically conducting openings that 
readily distribute the depolarization throughout the myocardium (Katz, 2005). 
 Arteries are thick-walled vessels that transport blood away from the heart. Arteries 
have muscle coated walls to sustain high pressure and flow. The elastic wall of the vessel 
pulsates with the blood flow, and evens out the blood flow in the smaller vessels. Blood 
pressure in the ascending aorta is the same as in the left ventricle, and is gradually lower 
in smaller vessels, reaching an average pressure of 17mmHg in the capillaries. Arteries 
branch into smaller arterioles and finally form capillary vessels. Arterioles control blood 
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flow and pressure by contracting or dilating according to the needs of the tissue (Guyton 
and Hall, 2000). Blood flow in a vessel is directly proportional to the fourth power of the 
radius of the vessel. Thus small differences in the diameter of the artery greatly influence 
the amount of blood flow in the tissue (Heil and Schaper, 2004). In metarterioles or 
 
  
 
From capillaries blood flows to venules, thin walled small veins that function as an 
entry point for inflammatory cells into the tissues (Zarbock and Ley, 2008). Venules 
connect to form larger veins. Blood pressure in the veins is low, and unidirectional flow is 
maintained by presence of valves preventing back flow. In the limbs contractions of the 
surrounding muscles push blood towards the heart. Veins have large luminal volume and 
are able to control the amount of blood available for tissues by constricting or enlarging. 
Veins connect and finally form the inferior and superior vena cavas, large veins that deliver 
oxygen poor blood back to the right heart to be reoxygenated in the lungs. 
Hierarchy and structure of the vascular network are tightly regulated in normal 
adult tissues. Specific mechanisms prevent formation of arterio-venous shunts, excess 
arterialisation of the vessels and connections between lymphatic vessels and veins. These 
regulatory systems are likely highly dependent on level blood flow and pressure within the 
vessels after embryogenesis (Swift and Weinstein, 2009). In pathological situations such 
as tumor growth these mechanisms are disturbed creating non-hierarchical, immature 
vessels (Cao, 2009). 
Blood vessels of the heart 
 
 Coronary arteries originate from two openings in the ascending aorta, right above 
the aortic valve cusps. The left main coronary artery divides to form left anterior 
descending artery (LAD) and left circumflex artery (LCX). The right coronary artery (RCA) 
originates from the second orifice. The anatomy of the coronary arteries varies between 
individuals, but generally LAD is responsible for the circulation in the anterior wall of the 
left ventricle and septum, LCX for the lateral wall and RCA for most of the right ventricle 
and posterior wall of the left ventricle. LAD further divides to diagonal branches that supply 
the left ventricular wall, septal branches that supply the anterior part of the intraventricular 
septum and right ventricular branches. (Katz, 2005)  
  
terminal arterioles the continuous smooth muscle layer 
is replaced by patchy pericyte coverage of the 
endothelial cell (EC) layer. Capillaries form an interface 
for oxygen and nutrient delivery to the tissues (Figure 
1). The diameter of a capillary vessel is approximately 
equal to the diameter of a red blood cell, which 
facilitates the diffusion of oxygen through the capillary 
endothelium. Capillary walls are also highly permeable 
to water and nutrients. Transport of water and nutrients 
mainly occurs via intercellular clefts. A smooth muscle 
cell (SMC) in the end of the metarteriole controls the 
blood flow to a capillary. Function of this precapillary 
sphincter is controlled by local oxygen tension in the 
tissue, and thus each tissue environment controls its 
own blood flow (Guyton and Hall, 2000). 
 
 
Figure 1. Microvessels in skeletal 
muscle. Larger vessels branch to form 
capillaries running parallel to muscle 
fibers. CD31 staining, magnification 
200X, scale bar 100µm. Lähteenvuo et 
al., unpublished result. 
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arterioles increasing the flow (Guyton and Hall, 2000). Human myocardium contains 
collateral vessels, small connecting arterioles between conducting arteries (Fulton, 
1963a). Collaterals are present in all individuals, but their number, size and anatomy vary 
considerably. Epicardial collateral vessels are smaller, 20-200µm in diameter, and are 
unlikely to significantly contribute to cardiac circulation under normal conditions while 
endocardial collateral network consists of larger, 100-200µm vessels. Due to a shorter 
period of blood flow in the endocardial vessels due to high pressure in the ventricles 
endocardial collateral vessels may play a role in normal perfusion of the myocardium 
(Fulton, 1963b). 
 
Metabolism of the heart 
 
 At rest the heart utilizes 70% of the oxygen in the arterial blood and 
cardiomyocytes use fatty acids as the main source of energy (Guyton and Hall, 2000). 
Cells in the conduction system of the heart, on the other hand, partially rely on anaerobic 
energy production (Henry and Lowry, 1983). Metabolism is regulated by the availability of 
oxygen and substrates for energy metabolism, dietary status, age, hormonal status, and 
work load of the heart. Fatty acids are the prime source of energy in the fasting individual, 
and fatty acid metabolism itself inhibits glycolysis (Mäki, 1998). Fatty acid metabolism is 
dependent on continuous delivery of oxygen, and when myocardium becomes ischemic 
metabolism shifts towards glycolysis (Neely and Morgan, 1974). Ischemia induces 
recruitment of glucose transporter GLUT4 to plasma membranes, and glucose moves 
down the concentration gradient across the cell membrane (Sun et al., 1994). Insulin 
increases glucose uptake via the same mechanism (Manchester et al., 1994). In addition 
to glucose uptake, ischemia also leads to breakdown of stored glycogen in the 
cardiomyocytes (Lopaschuk and Stanley, 1997). 
 
 
 
 
 
Coronary arteries run on the surface of the heart and 
branch into smaller arteries that penetrate deeper into 
the myocardium.The heart has a dense network of 
capillaries (approximately one capillary per 
cardiomyocyte) (Kumar V. et al., 2005)(Figure 2). The 
innermost layer of the myocardium (endocardium) also 
receives some blood directly form the ventricles. The 
coronary veins run alongside the arteries, and venous 
blood returns to the right atrium via the sinus 
coronarius located on the posterior side of the heart. 
Blood flow into the capillaries occurs mostly during the 
diastole when the intramyocardial pressure is on its 
lowest level. The heart receives 5-6% of the blood 
pumped from the left ventricle at rest, and the flow can 
rise up to 3-4-fold at stress. Increased demand for 
oxygen and energy induces relaxation of the coronary  
 
Figure 2. Microvessels in the heart. 
Capillaries form a dense network 
between muscle fibers. CD31 staining, 
magnification 200X, scale bar 100µm. 
Lähteenvuo et al., unpublished result. 
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CARDIOVASCULAR DISEASES 
 
Atherosclerosis 
 
 Atherosclerosis is the common pathogenic process behind ischemic diseases. 
Although the initial cause of the process remains unclear, subsequent steps include 
accumulation of lipids into the vascular wall, accumulation of inflammatory cells to the 
plaque and formation of neovasculature within the plaque. Changes in the vessel wall 
gradually occlude the vascular lumen and reduce the blood flow. A plaque becomes 
hemodynamically significant at stress when it occludes 75% of the vessel lumen and when 
the occlusion exceeds 90% it disturbs blood flow also at rest (Kumar V. et al., 2005). 
Threrefore the first manifestation of atherosclerosis is often ischemic pain during exercise. 
As the disease progresses tissues suffer from insufficient delivery of oxygen and nutrients 
also at rest. 
 
Peripheral arterial disease 
 
 Peripheral arterial disease manifests as intermittent pain during exercise. In 
chronic lower limb ischemia atherosclerotic plaques gradually occlude the arteries (Kumar 
V. et al., 2005). In critical limb ischemia complications such as ulcers or gangrene have 
developed as a result of ischemia. In acute limb ischemia, a vessel is suddenly occluded 
as a result of a thromboembolic event and tissue necrosis results within hours (Minar, 
2009). Exercise is the only efficient non-invasive treatment method, and treatment 
includes risk factor management and in some cases medication. Invasive treatment 
options include percutaneous transluminal angioplasty and by-pass grafting (Slovut and 
Sullivan, 2008). However, 20-30% of these patients cannot be treated with conventional 
therapies and amputation is the only treatment option (Dormandy and Rutherford, 2000). 
 
Myocardial ischemia 
 
 Myocardial ischemia is caused by a lack of oxygen in the heart. In chronic 
myocardial ischemia blood flow is reduced as a result of the atherosclerotic process. 
Developing atherosclerotic plaques gradually occlude the vessel lumen. 90% of the vessel 
lumen can be occluded without reduction in blood supply at rest, while 75% reduction in 
the vessel diameter causes significant reduction of blood flow in stress (Kumar V. et al., 
2005). Gradual occlusion of the coronary arteries directs blood to collateral arteries that 
respond by increasing their diameter both by dilation and cell proliferation. The ability to 
develop these collateral arteries is individual, but in optimal situation collateral flow can be 
sufficient to replace the flow of a whole main coronary vessel at rest (Schaper, 2004).  
 Acute myocardial ischemia (AMI) is the result of a sudden blockage of a coronary 
vessel (Boersma et al., 2003). Acute myocardial infraction is thought to be caused by 
rupture of an atherosclerotic plaque or by endothelial damage. Damage or rupture of the 
endothelial cell layer reveals a thrombogenic surface and a blood clot comprising of 
thrombocytes and fibrin may develop. Alternatively, plaque rupture may release plaque 
contents to the circulation causing a thrombus downstream or form a mechanical block at 
the rupture site (Kumar V. et al., 2005). Compensatory arterial growth is too slow to 
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restore the circulation in AMI, and within hours a permanent infarction scar starts to 
develop. Cardiomyocyte damage starts within minutes after cessation of oxygen supply 
and contraction ceases within 60 seconds and cardiomyocytes begin to die after 15-40 
minutes (Katz, 2005).  
 If circulation is not restored, irreversible damage occurs. In the areas where blood 
supply is cut off completely cells begin to die by coagulation necrosis (Kumar V. et al., 
2005). Blood vessels in the border of the ischemic area become leaky, and inflammatory 
cells infiltrate into the forming scar. Within the first couple of days inflammatory cells are 
mostly neutrophils, but around day 7 monocytes/macrophages become predominant. 
Necrotic cardiomyocytes are first replaced by granulation tissue which starts to remodel 
into a fibrotic scar. Fibroblasts proliferate and secrete collagen, and both resident and 
bone marrow (BM) derived cells begin to differentiate into myofibroblasts. The myocardial 
infarction scar is completely formed approximately 2 months after AMI (Frangogiannis et 
al., 2002). 
 If a significant portion of the myocardial wall is damaged, myocardial function is 
affected and complications may develop. The infarction scar does not contract and is 
mechanically weaker than normal myocardial wall. Fibrosis occurs throughout the 
myocardium. Fibrotic myocardium is electrically unstable because the normal conduction 
of the depolarization wave is disturbed by the electrically inactive fibrotic scar increasing 
the risk of fatal ventricular arrythmias (Rothman et al., 1997). The healthy part of the 
myocardial wall begins to hypertrophy to compensate for the impaired function of the scar 
area, and the ventricle starts to dilate leading to cardiac dysfunction and eventually cardiac 
failure. Initially hypertrophy is accompanied by capillary growth, but eventually hypertrophy 
proceeds without compensatory growth of new blood vessels.  
 
Metabolic adaptation to ischemia 
 
In the border zone of the infarction area where some but insufficient perfusion 
remains, cardiomyocytes assume a hibernating phenotype. They cease to contract to save 
energy and convert their metabolism towards less oxygen demanding glycolysis. Under 
normal conditions cardiomyocytes use 75% of their oxygen consumption for contraction 
(McKeever et al., 1958; Izzi et al., 1991) and therefore only a low level of perfusion is 
required to maintain cell viability in resting cardiomyocytes (Gewirtz et al., 1994). During 
longer periods of insuffient blood flow cardiomyocytes may also dedifferentiate to increase 
their resistance to ischemia. They accumulate glycogen in their cytoplasm, and start to 
express fetal type cardiomyocyte markers such as alpha smooth muscle actin (α-SMA) 
and desmin (Dispersyn et al., 2002). The function of the hibernating myocardium may 
recover if blood flow is restored, but responses between patients vary considerably. 
Metabolic changes in the ischemic myocardium have been extensively studied for 
a century. Interpretation of these results is complicated by different criteria to identify 
ischemic and hibernating areas of the myocardium and by use of different animal models 
and clinical settings. However, the switch to glucose metabolism seems to be a double-
edged sword. If the period of ischemia is brief and blood flow is restored shortly, or a low 
level of perfusion is maintained, glycolysis has a beneficial effect. Glycolysis requires less 
oxygen per mole of adenosine triphosphate (ATP) created than fatty acid metabolism, and 
can be maintained also under anaerobic conditions. However, if glycolysis is carried out in 
anaerobic conditions, lactate starts to build up in the tissue, pH becomes acidic and 
cellular damage results. Restoration of tissue blood flow is therefore essential to save 
myocardial cells and rescue myocardial function. 
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GROWTH OF BLOOD VESSELS 
 
Formation of the cardiovascular system 
 
 The formation of the cardiovascular system begins by the formation of an 
immature vascular plexus that gives rise to the dorsal aorta, cardinal vein and vessels of 
the yolk sac. Immature hemangioblasts differentiate to form both blood vessels and blood 
cells (Swift and Weinstein, 2009). After initial formation of the primitive vascular plexus, 
subsequent blood vessel growth is stimulated by hypoxia in the growing embryo, and 
primitive blood vessels sprout to invade developing organs (Risau, 1997). 
 Arteries and veins have different functions, and they specialize to meet the 
physiological requirements. Arteries acquire a thicker muscle layer, and arterial endothelial 
cells express specific surface markers such as ephrinB2 while veins are more permeable, 
have a thinner muscle layer and express ephrinB4 (Gerety et al., 1999). Angioblasts 
commit to arterial and venous lineages before the heart starts to pump blood. Notch 
pathway regulates this lineage commitment and bidirectional ephrin signaling maintains 
the separation and guides blood vessel branching. Also Nrp-1 has been suggested to be 
involved in vascular hierarchy formation in the retina through different VEGF-A isoforms 
(Stalmans et al., 2002). Arterio-venous identity is reprogrammable even in the adult and is 
regulated by Notch signaling and orphan nuclear receptor CoupTFII (You et al., 2005; 
Roca and Adams, 2007) and by adaptation to alterations in blood flow (Garcia-Cardena et 
al., 2001; le Noble et al., 2004). 
 
Growth of blood vessels in adult 
 
Physiological angiogenesis in adults is practically limited to blood vessel growth in 
the endometrium during every menstrual cycle. Blood vessel growth occurs in many 
common pathological conditions, such as wound healing, psoriasis and rheumatoid 
arthritis (Carmeliet, 2003). Angiogenesis is also required for tumor growth. Tumors both 
recruit blood vessels from surrounding tissues and stimulate blood vessel growth by 
producing angiogenic growth factors (Folkman and Shing, 1992). Angiogenesis is an 
endogenous repair mechanism also in adult heart and skeletal muscles both in acute 
infarction and in chronic ischemia. 
 
Blood vessel growth in myocardial ischemia 
 
 Growth of new blood vessels is an endogenous response to ischemia. Maintaining 
the normal function of the myocardial tissue requires both growth of large arteries to 
replace the occluded coronary vessel (arteriogenesis) and growth of capillary vessels to 
deliver oxygen and nutrients to the myocardial cells (angiogenesis) (Scholz et al., 2001). 
Collateral arteries are small arteries that form connections between conducting arteries. 
When a coronary artery occludes, pressure in collateral arteries rises and they dilate within 
seconds. If flow remains high, collaterals begin to grow. As a result, blood flow in collateral 
arteries can double in 2-3 days (Heil and Schaper, 2004). Thus forming collateral 
circulation can at least partially compensate the diminished blood flow in the periphery. 
The potency to form collateral arteries varies between individuals, and requires weeks to 
months to reach blood flow sufficient to compensate the flow of the original artery even at 
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rest. According to the Poiseuille’s law, flow is proportional to the 4th potency of the vessel 
diameter and hence a large number of smaller arteries are required to replace a large 
diameter coronary artery (Heil and Schaper, 2004). 
Cells in the ischemic myocardium start to produce angiogenic growth factors such 
as VEGF-A (Li et al., 1996) (Figure 3), and inflammatory cells present in the infarction 
border zone are shown to be able to produce a wide variety of growth factors. Blood 
vessels dilate and start to grow towards the angiogenic stimulus to increase blood flow in 
the ischemic area. Endogenously growing capillary network is not able to keep up with the 
developing tissue damage and later tissue growth due to ventricular remodeling, and 
apoptotic cell death continues for weeks after the ischemic event (Narula et al., 1996; 
Cheng et al., 1996).  
 
 
MECHANISMS OF BLOOD VESSEL GROWTH 
 
Vasculogenesis and stem cells in blood vessel growth 
 
Vasculogenesis is growth of blood vessels from vascular progenitor cells. It is the 
first step in the formation of the cardiovascular system in the embryo. Blood vessel 
formation and maintenance have been suggested to require vasculogenesis also in adult 
tissues, but the biological significance and mechanism remain unclear (Sieveking and Ng, 
2009). Incorporation of bone marrow (BM) derived cells to normal myocardium and blood 
vessels has been demonstrated in humans (Gunsilius et al., 2000; Quaini et al., 2002). 
Several studies have also provided indirect evidence on their role in endogenous repair 
mechanisms. Cells are recruited from the BM after vascular injury and by expression of 
several cytokines including VEGF (Gill et al., 2001; Kalka et al., 2000). Acute myocardial 
infarction increases plasma levels of VEGF and increases mobilization of BM derived cells 
resembling ECs in vitro (Shintani et al., 2001). The amount of circulating progenitor cells 
has also been inversely correlated with known clinical risk factors for cardiovascular 
diseases and endothelial function (Hill et al., 2003). Although the recruitment of bone 
marrow derived cells to peripheral circulation has been observed in various situations, the 
role of these cells in vascular repair in vivo has not been convincingly demonstrated.  
Figure 3. Endegenous angiogenesis in 
ischemic human myocardium. In 
normal myocardium VEGF production 
is low (a) and capillary vessels are 
small (b). Cells in the ischemic 
myocardium begin to produce VEGF-A 
(c) and other growth factors inducing 
endogenous angiogenesis and 
capillary enlargement (d) to increase 
blood flow in the ischemic area. 
Magnification 200X, scale bar 100µm. 
Lähteenvuo J, unpublished result. 
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 Several populations of multipotent BM derived cells have been identified, and 
their potency in blood vessel regeneration has been tested in several preclinical and 
clinical studies (Rafii and Lyden, 2003). However, varying markers to identify and enrich 
the cell populations, different disease models and human applications the cells have been 
studied in, different delivery methods and end point measurements have produced 
conflicting results. 
Bone-marrow derived stem cells have been reported to incorporate directly into 
angiogenic vessels forming both endothelial and smooth muscle cells during physiological 
and pathological angiogenesis and to improve the function of ischemic tissues (Gunsilius 
et al., 2000; Kocher et al., 2001; Orlic et al., 2001). However, the capacity of bone-marrow 
derived cells to incorporate into vessel structures and to differentiate into mature 
endothelial or myocardial cells has been questioned (Ziegelhoeffer et al., 2004; Murry et 
al., 2004; Balsam et al., 2004). 
Several studies have proposed that instead of incorporation into blood vessels BM 
derived cells may facilitate neovessel growth by homing into angiogenic tissue and 
producing angiogenic factors (Kinnaird et al., 2004a). Growth factor -producing 
mononuclear cells have been shown to be essential for collateral formation, and several 
studies have demonstrated the presence of BM derived cells in perivascular position in 
developing blood vessels but no incorporation to vascular endothelium (Ziegelhoeffer et 
al., 2004; Kinnaird et al., 2004b). BM derived cells may also fuse into cells in host tissues. 
Thus far cell fusion appears to be a rare phenomenon in vivo, and the biological role of the 
cell fusion demonstrated iv vitro remains unclear (Terada et al., 2002; Ying et al., 2002). 
In addition to BM derived cells, adult tissues have been suggested to contain 
resident progenitor cells that can contribute to vasculogenesis and regeneration of 
ischemic tissues. Skeletal muscles contain populations of precursor cells capable of 
transdifferentiating into endothelial cells and smooth muscle cells (Majka et al., 2003) but 
not cardiomyocytes (Reinecke et al., 2002). The presence of myocardial progenitor cells 
has been demonstrated in humans and their ability to differentiate into cardiomyocytes, 
endothelial cells, smooth muscle cells and to integrate into ischemic myocardium has been 
shown in experimental animal models (Bearzi et al., 2007; Beltrami et al., 2003).  
Reprogramming adult cells to pluripotent stem cells (iPS) is a new method to 
create stem cell populations. iPS can be derived from the skin and differentiated into 
multiple cell types including endothelial cells, cardiomyocytes and smooth muscle cells 
(Tulloch et al., 2008). 
The use of BM or tissue derived stem cells for treatment of ischemic diseases 
poses several safety issues. Unselected populations of BM-derived cells may induce 
inflammation and produce excessive amounts of growth factors inducing poorly organized 
vascular structures, vascular leakage and edema. Transplanted cells may fail to 
differentiate and incorporate into host tissue, possibly leading to tumor formation or 
disturbances in host tissue function, such as arrythmias in the myocardium (Villa et al., 
2007; Fernandes et al., 2006). BM transplantation has also been shown to lead to tissue 
calcification and fibrosis (Yoon et al., 2004; Wang et al., 2001b). Lack of specific markers 
and incomplete understanding of the functions of different cell populations may lead to 
selection of suboptimal cell fractions. The majority of the progenitor cell experiments have 
been performed on young, healthy animals, and progenitor cell number is lower and 
function is possibly impaired in elderly, hypercholesterolemic and diabetic individuals 
(Moresi et al., 2005; Krankel et al., 2005; Chen et al., 2004; Vasa et al., 2001).  
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Angiogenesis 
 
 Angiogenesis is the growth of new capillary vessels by endothelial cell (EC) 
proliferation and migration from pre-existing vessels. Endogenous angiogenesis is driven 
by hypoxia. Lack of oxygen stimulates expression of hypoxia-sensitive factors e.g. 
hypoxia-inducible factor 1α (Hif1-α) expression, and this in turn activates production of 
angiogenic growth factors (Marti, 2005; Fong, 2008). During embryogenesis, angiogenesis 
is the mechanism by which blood vessel growth keeps up with the growth of organs. 
Angiogenesis is also the main mechanism of blood vessel growth in the adult (Risau, 
1997). 
 Angiogenesis is a multi-step process. In quiescent state ECs are tightly attached 
by intercellular junctions and the turnover rate of ECs is low (Ahn et al., 2008). The 
angiogenic process is initiated by vessel dilation, increase in vascular permeability, 
disattachment of pericytes, degradation of basement membrane and release of proteolytic 
factors altering the interstitial environment and releasing angiogenic factors from the 
extracellular matrix (Jain, 2003). Leakage of plasma proteins creates a matrix for 
endothelial cell migration rich in growth factors and proteases. Proliferation and migration 
of ECs produce first chords of ECs that connect to other blood vessels and then develop a 
lumen.  
 Immature neovessel network is then remodeled to respond to the metabolic needs 
of the tissue. Continuing hypoxia induces production of growth factors, while cessation of 
growth factor production in normoxic or hyperoxic tissue leads to pruning of the vascular 
network and vessel maturation (Dor et al., 2001). If a vessel is not needed, tissue 
regulation decreases blood flow eventually leading to EC apoptosis (Sho et al., 2001). 
Blood vessels acquire pericyte coverage, either by proliferation of pre-existing pericytes or 
by differentiation of fibroblasts into myofibroblasts and further to mural cells (Chambers et 
al., 2003; Jain, 2003). Pericyte coverage has been proposed to be a hallmark of vessel 
stabilization (Benjamin et al., 1998), but further maturation may be required as vessels 
with apparent pericyte coverage have been shown to regress (Rissanen et al., 2005). 
Finally, new basement membrane is secreted and blood vessels assume quiescent state 
(Abtahian et al., 2003).  
Arteriogenesis 
 
 Arteriogenesis is the growth of collateral arteries. Collateral arteries in healthy 
tissues are small, thin walled vessels forming anastomoses between arteries. Collateral 
growth has been thought to be dependent on pre-existing collateral channels found widely 
in different species and tissues. (Helisch 2003.) The human heart was demonstrated to 
have arterial anastomoses almost a hundred years ago (Gross, 1921). Unlike 
angiogenesis, arteriogenesis is not controlled by hypoxia (Deindl 2001). When an artery is 
occluded, blood pressure distally from the occlusion falls, and a steep pressure gradient 
develops (Helisch 2003). As a result, flow is increased in pre-existing collateral arteries 
increasing fluid shear stress, and pressure-related forces on the vessel wall (Heil 2004). 
Endothelial cells respond within hours, shown by ultrastructural changes. Nitric oxide 
released by the ECs induces dilation of the vessels, further increasing flow and relaxing 
distal arterioles (Nishida et al., 1992). Adhesion molecule expression is up-regulated within 
12 hours, and monocytes adhere to endothelium and start to accumulate in the vessel wall 
(Scholz 2000). Monocytes have been shown to be important mediators of collateral 
growth, possibly via production of proteases and growth factors. Endothelial and smooth 
muscle cell proliferation start 12-24 hours after the initiation of the growth process. 
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Proliferation has been suggested to be stimulated by either local production of growth 
factors, or by direct pressure stimulation of the cells. The internal elastic lamina is partially 
degraded by proteases, allowing direct contact between endothelial cells and smooth 
muscle cells and smooth muscle cell migration (Scholz 2000).  
 Collateral growth continues until pressure and shear stress in the growing 
collateral returns to normal level. Collateral growth has been shown to compensate 
diminished blood flow in humans. Well-developed collaterals can replace the flow of one of 
the main coronary arteries, and collateral flow correlated with clinical symptoms and 
outcome of patients suffering from myocardial ischemia in a 10-year follow-up study 
(Rockstroh and Brown, 2002). Arteries formed by collateral growth are ultrastructurally 
normal, apart from increased amount of collagen between the smooth muscle cells 
(Scholz et al., 2000).  
 
Blood vessel growth and vascular permeability 
 
 Growth of blood vessels is accompanied by an increase in the permeability of the 
vessels. ECs in their quiescent state are tightly attached to each other and form a 
continuous layer in the vessel wall. EC contacts induce signals to maintain this quiescent 
state and inhibit proliferation (Holash et al., 1999). Angiogenesis is initiated by 
disattachment of the pericytes surrounding the capillary and by breakdown of the 
basement membrane by proteases. ECs are able to proliferate after intercellular contacts 
have been disrupted. This disruption of normal vessel structure leads to leakiness of the 
growing vessels. Other mechanisms are also involved in the plasma protein leakage 
observed after growth factor administration. Vascular endothelial growth factor (formerly 
vascular permeability factor, Vpf) is a potent inducer of vascular permeability. Vascular 
leakiness is induced within seconds after administration, at a concentration 1/50 000 
compared to that of histamine (Senger et al., 1983). This effect is likely due to increased 
permeability at the intracellular junctions of the ECs. In addition, mechanisms involving 
transcellular transport through ECs have been proposed (Bates and Harper, 2002; Nagy et 
al., 2008).  
 Several approaches have been published to inhibit vascular permeability. Some 
growth factors have been published to induce angiogenesis without vessel leakiness but 
results in large animal models have been in conflict with this data (Luttun et al., 2002). 
Also combination treatments with either factors naturally involved in the signaling of the 
quiescent state (Ang-1) (Thurston et al., 2000) or with factors stimulating pericytes and 
therefore stabilizing the vessel wall (PDGF) have been proposed. As attempts to uncouple 
angiogenesis and vascular permeability have not been successful in large animal models 
(Lähteenvuo and Rissanen, unpublished results) and uncoupling these events seems 
conceptually challenging, other approaches such as reduction of tissue edema by inducing 
lymphatic vessel wall should be explored. 
 
MOLECULES REGULATING BLOOD VESSEL GROWTH 
 
 Growth of blood vessels is a multi-step process induced by orchestrated function 
of growth factors and their receptors. Blood vessel growth can be triggered by hypoxia, 
increased flow in the vessel or by production of angiogenic growth factors. To produce a 
balanced growth of functional blood vessels requires coordinated expression of several 
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factors and responses in several cell types. The focus is on VEGFR-1, VEGFR-2 and Nrp-
1 receptors and their ligands (Figure 4). 
 
Figure 4. Vascular endothelial growth factors and receptors regulating angiogenesis. 
Vascular endothelial growth factor receptor-1 (VEGFR-1) 
 
 VEGFR-1 (Flt-1) is required for the development of the cardiovascular 
system. VEGFR1 null mice die by embryonic day 9 due to lack of formation of organized 
blood vessels (Fong et al., 1995). However, only the extracellular part of the receptor 
seems to be required for the normal development, as mice lacking only the intracellular 
part of the receptor are healthy and fertile (Hiratsuka et al., 1998). VEGFR-1 is expressed 
in ECs, osteoblasts, monocytes/macrophages, pericytes, placental trophoblasts, renal 
cells and some hematopoietic stem cells (Ferrara et al., 2003). VEGFR-1 is up-regulated 
in hypoxic environment directly by a hypoxia responsive element (Marti and Risau, 1998; 
Gerber et al., 1997) and in angiogenic vessels (Plate et al., 1993). Interestingly, in hypoxia 
VEGFR-1 is diffusely up-regulated in both ECs and cardiomyocytes (Marti and Risau, 
1998; Carmeliet et al., 2001) and on coronary smooth muscle cells (Ishida et al., 2001). In 
addition, in the ischemic myocardium, an increased proportion of VEGFR-1 is the 
membrane-bound form suggesting a role for intracellular signaling via VEGFR-1 
(Carmeliet et al., 2001).  
VEGFR-1 binds VEGF-A, Placental Growth factor (PlGF) and VEGF-B (de et al., 
1992; Park et al., 1994; Olofsson et al., 1998). VEGF-A and PlGF have been shown to 
phosphorylate different residues in VEGFR-1, thus possibly inducing ligand-specific 
functions via the same receptor (Autiero et al., 2003). VEGFR-1 has been suggested to be 
involved in several pathological conditions, and inhibition of VEGFR-1 has been shown to 
inhibit tumor growth, atherosclerotic plaque growth and vulnerability, and arthritic joint 
destruction (Luttun et al., 2002). During angiogenesis VEGFR-1 has been suggested to be 
involved in blood vessel sprouting and EC migration (Kearney et al., 2004). In addition, 
VEGFR-1 stimulation induces monocyte chemotaxis (Clauss et al., 1996). 
Monocytes/macrophages have been shown to be essential for arteriogenesis, and 
accordingly VEGFR-1 ligands have been shown to induce collateral artery growth (Pipp et 
al., 2003).  
VEGFR-1 is naturally expressed also in a soluble form. The soluble form of 
VEGFR-1 may function as a decoy receptor to limit the bioavailability of its ligands 
(Hiratsuka et al., 1998) and to prevent blood vessel growth in avascular tissues such as 
the cornea (Ambati et al., 2006). Since VEGFR-1 has a relatively weak tyrosine kinase 
activity, it was suggested to function as a decoy receptor sequestering VEGF-A and thus 
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inhibiting VEGFR-2 activation (Park et al., 1994). However, in vitro studies suggest that 
the soluble form of VEGFR-1 may mediate migration and branching via binding to 
extracellular matrix components (Orecchia et al., 2003; Kappas et al., 2008). Although 
healthy and fertile, mice only expressing the sVEGFR-1 have impaired monocyte 
migration in response to VEGF (Hiratsuka et al., 1998).   
Placental growth factor (PlGF) 
 
 PlGF is expressed only in low levels in developing embryo but is expressed in the 
placenta, heart, brain, skeletal muscle and lungs in the adult (Persico et al., 1999) and in 
both endothelial cells and in lower levels in pericytes (Zhao et al., 2004). PlGF deficient 
mice are healthy and fertile, but they recover poorly after experimental myocardial 
infarction or hindlimb ischemia (Carmeliet et al., 2001). PlGF is expressed in three 
isoforms, PlGF-1, -2 and -3 (Cao et al., 1997; Park et al., 1994). PlGFs binds to VEGFR-1 
(Park et al., 1994; Sawano et al., 1996) and PlGF-2 also binds to heparin sulphates and is 
a ligand for Nrp-1 receptor (Migdal et al., 1998). PlGF forms biologically active 
heterodimers with VEGF-A that are able to bind VEGFR-2 (Cao et al., 1996a). 
Interestingly, also PlGF homodimers have been shown to up-regulate (Odorisio et al., 
2002) and phosphorylate VEGFR-2 (Autiero et al., 2003) although no direct binding is 
observed. 
 PlGF is not up-regulated by hypoxia in transcriptional level, but increases in 
protein levels of both PlGF/VEGF heterodimer and PlGF homodimer suggest post-
transcriptional regulation (Cao et al., 1996b). In addition, VEGF-A and hyperglycemia up-
regulate PlGF in ECs in vitro (Zhao et al., 2004).  
PlGF has been reported to be a weak EC mitogen in vitro (Park et al., 1994; 
Sawano et al., 1996) but to induce EC proliferation and angiogenesis in vivo (Ziche et al., 
1997). The effect of PlGF on vascular permeability remains controversial. PlGF was 
originally shown to be a weak inducer of acute vascular permeability (Park et al., 1994), 
but was later shown to increase protein extravasation and edema after both acute and 
prolonged expression (Odorisio et al., 2002; Oura et al., 2003). PlGF induced 
angiogenesis in mouse myocardial infarction, hindlimb ischemia and skin angiogenesis 
models without increasing vascular permeability or edema (Luttun et al., 2002). PlGF 
induces monocyte migration via membrane-bound form of VEGFR-1 (Hiratsuka et al., 
1998), and has been reported to induce arteriogenesis via monocyte recruitment (Pipp et 
al., 2003).  
Due to conflicting results, weak signaling via VEGFR-1 and weak potency in vitro, 
several indirect mechanisms of function have been suggested for PlGF. PlGF has been 
suggested to potentiate the effects of VEGF-A (Park et al., 1994), function via PlGF/VEGF 
heterodimer formation (Cao et al., 1996a) or by modulation of VEGFR-1/VEGFR-2 
interactions (Autiero et al., 2003).  
 
Vascular endothelial growth factor-B (VEGF-B) 
 
 VEGF-B is produced in two isoforms, VEGF-B167 and VEGF-B186 that are further 
proteolytically processed (Olofsson et al., 1996b). VEGF-B186 is readily soluble, while 
VEGF-B167 binds heparan sulphate proteoglycans. VEGF-B binds to VEGFR-1 and Nrp-1 
(Olofsson et al., 1998; Mäkinen et al., 1999). VEGF-B167 is the predominant form in adult 
tissues, and it is expressed in myocardium, in a subset of skeletal muscle fibers and the 
pancreas (Olofsson et al., 1996a). VEGF-B expression in the embryonic and postnatal 
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myocardium coincides with coronary vessel and capillary development in the ventricles, 
but is mainly seen in the myocytes (Bellomo et al., 2000). VEGF-B was also shown to be 
up-regulated in ischemic hind limb muscles in mice (Silvestre et al., 2003). In one genetic 
backround VEGF-B deficient mice have smaller hearts and they recover poorly after 
experimental myocardial infarction (Bellomo et al., 2000), while in other genetic 
background mice have ECG abnormalities (Aase et al., 2001) but in both cases animals 
are viable and fertile. 
VEGF-B increases EC proliferation (Olofsson et al., 1996a) and naked plasmid 
transduction of both VEGF-B167 and VEGF-B186 was shown to induce angiogenesis in 
mouse hindlimbs in a nitric oxide dependent manner (Silvestre et al., 2003). In several 
other settings and tissue environments, such as in the adventitia (Bhardwaj et al., 2003) 
and skin (Kärpänen et al., 2008), VEGF-B has been shown to be a weak or inefficient 
inducer of angiogenesis. Both prolonged and transient adenoviral VEGF-B expression 
have been shown to induce cardiac hypertrophy without attenuating the heart function 
(Tirziu et al., 2007; Kärpänen et al., 2008).  
VEGF-B has recently been suggested to have metabolic functions. Over-
expression of VEGF-B leads to cardiac hypertrophy and alterations in lipid metabolism 
(Kärpänen et al., 2008). In addition, VEGF-B may function as a survival factor. It has been 
shown to inhibit apoptosis (Li et al., 2008) and to protect both brain and myocardium from 
ischemic injury (Sun et al., 2004; Kärpänen et al., 2008).  
Vascular endothelial growth factor receptor-2 (VEGFR-2) 
 
VEGFR-2 (Flk-1) is essential for the formation of the cardiovascular system. 
VEGFR-2 null mice die on embryonic day (E)8.5 due to defects in the hematopoietic and 
EC precursor differentiation (Shalaby et al., 1995). VEGFR-2 is expressed on ECs, 
neuronal cells, osteoblasts, pancreatic duct cells, megacaryocytes and hematopoietic 
stem cells (Shibuya and Claesson-Welsh, 2006). VEGFR-2 expression is autoregulated by 
its ligands VEGF-A, VEGF-C and VEGF-D (Tammela et al., 2005a). VEGFR-2 has been 
shown to be up-regulated in ischemic tissues in vivo, for example in ischemic myocardium 
(Li et al., 1996).  Since no hypoxia responsive element has been identified, regulation has 
been suggested to be indirect, either via a paracrine mechanism (Brogi et al., 1996) or 
post-transcriptional mechanisms such as RNA stabilization (Waltenberger et al., 1996). 
VEGFR-2 and VEGFR-1 are capable of forming dimers, and dimer formation may mediate 
ligand-specific functions of these receptors. Prostaglandin production and more efficient 
arteriogenic response have been suggested to be functions of this receptor dimer (Neagoe 
et al., 2005).  
 Several phosphorylation sites and signaling pathways have been identified for 
VEGFR-2 (Shibuya and Claesson-Welsh, 2006). VEGFR-2 mediates EC migration, 
proliferation, vascular permeability and angiogenesis (Gille et al., 2001; Ferrara et al., 
2003). Nitric oxide has been shown to be a mediator of many of these functions (Zachary 
and Gliki, 2001). 
Vascular endothelial growth factor-A (VEGF-A) 
 
 VEGF-A was identified from ascites fluid as a factor inducing vascular permeability 
(Senger et al., 1983). VEGF-A is required for vascular development. VEGF-A null mice die 
on E8-9 due to defects in blood island formation, EC development and vascular formation 
(Ferrara et al., 1996). Even deletion of a single VEGF allele leads to death at E11-12 due 
to defects in cardiovascular formation (Carmeliet et al., 1996; Ferrara et al., 1996). VEGF-
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A is produced in at least six different isoforms due to alternative splicing producing 
proteins containing 121, 145, 165, 183 or 189 amino acids. The isoforms vary in their 
solubility: the shortest isoform VEGF121 is relatively freely soluble, about half of VEGF165 
bind to heparin sulphate proteoglycans and VEGF189 is tightly bound in extracellular matrix 
(Tammela et al., 2005a). VEGF-A isoforms are capable of forming growth factor gradients 
guiding blood vessel growth due to varying solubility properties of the different isoforms. In 
addition, proteins bound to the extracellular matrix can be mobilized via proteolysis and 
thus heparin binding may regulate the bioavailability of VEGFs via activation of matrix-
bound proteins by proteolytic cleavage (Houck et al., 1992). In addition, different VEGF-A 
isoforms have different receptor binding profiles. For example, VEGF-A121 only binds Nrp-1 
(Pan et al., 2007) while VEGF-A165 binds to both Nrp-1 and Nrp-2 (Ferrara et al., 2003). 
VEGF-A expression is increased in hypoxic conditions by hypoxia inducible factor (HIF) 
(Shweiki et al., 1992). VEGF-A induces proliferation of both EC and smooth muscle cells 
(Parenti et al., 2002). VEGF-A has been shown to regulate the expression of glutein 
transporter GLUT1 implicating a role in metabolic regulation in ischemia (Pekala et al., 
1990).  
 
Vascular endothelial growth factor-D (VEGF-D) 
 
 VEGF-D is produced and secreted as a full length protein dimer. After secretion 
proprotein convertases (PC) furin, PC5 and PC7 and plasmin cleave the C- and N-terminal 
propeptides increasing the receptor binding affinity to VEGFR-2 by 17 000 –fold (McColl et 
al., 2003; McColl et al., 2007). The proteolytic processing is therefore required for the 
angiogenic activity of VEGF-D (Stacker et al., 1999). The proteolytically processed form of 
VEGF-D, VEGF-D∆N∆C has been shown to induce angiogenesis in cornea and skeletal 
muscle, while adenoviral over-expression of VEGF-D∆N∆C in the skin induced both blood 
and lymphatic vessel growth (Byzova et al., 2002). VEGF-D null mice are healthy and 
fertile and do not display any cardiovascular deformities (Baldwin et al., 2005). In adult 
tissues VEGF-D is mainly expressed in the heart, lung, skeletal muscles, in the intestine 
(Achen et al., 1998) and in both normal and atherosclerotic arteries (Rutanen et al., 2003).  
Although VEGF-D is not required for embryonic development of blood vessels, it was 
shown to be up-regulated in hypoxia-driven angiogenesis in vitro (Nilsson et al., 2004) and 
in skeletal muscles of diabetic mice in vivo (Kivela et al., 2007). In vitro also hypoxia and 
cell-cell contacts have been shown to up-regulate VEGF-D (Teng et al., 2002; Orlandini 
and Oliviero, 2001). Transgenic over-expression of VEGF-D∆N∆C increases capillary 
density in the heart and skeletal muscles and improves recovery after ischemia 
(Kärkkäinen et al., 2009).  VEGF-D over-expression had also been shown to promote 
tumor growth and metastasis (Kopfstein et al., 2007; Kärkkäinen et al., 2009).  
 
Vascular endothelial growth factor-E (VEGF-E) 
 
 VEGF-E is a homologue of VEGF-A expressed in the poxvirus orf virus (Lyttle et 
al., 1994). It binds to VEGFR-2 (Meyer et al., 1999) and Nrp-1 (Wise et al., 1999). VEGF-E 
has been shown to induce angiogenesis via NO production (Cudmore et al., 2006) and to 
improve wound healing (Zheng et al., 2007). Transgenic over-expression of VEGF-E was 
shown to induce blood vessel growth without increasing vascular permeability (Kiba et al., 
2003).  
 32 
Neuropilin-1 (Nrp-1) 
 
Neuropilin-1 (Nrp-1) binds both class 3 semaphorins and VEGFs. It is involved in 
axonal guidance during development of the nervous system. In adult tissues Nrp-1 was 
shown to be expressed in the placenta, myocardium and in arterial endothelium and to a 
lesser extent in kidney, skeletal muscle and pancreas by Northern blotting (Soker et al., 
1998). Nrp-1 also plays a role in the formation of the cardiovascular system in the embryo. 
Nrp-1 null mice display defects in the heart development, formation of large arteries and 
vascular networks in the yolk sac (Kawasaki et al., 1999), whereas over-expression leads 
to increase in vessel density, formation of dilated hemorrhagic vessels and cardiac 
malformations (Kitsukawa et al., 1995). Nrp-1 is also over-expressed in regions of 
physiological and pathological angiogenesis, suggesting a role in growth of blood vessels. 
In addition, manipulation of flow also alters neuropilin expression patterns (le Noble et al., 
2004).  
Nrp-1 is a transmembrane glycoprotein that has only a short cytoplasmic domain. 
Only the extracellular domain of Nrp-1 is required in the neuronal guidance (Nakamura et 
al., 1998) and enhancement of VEGFR-2 phosphorylation (Yamada et al., 2001), while 
intracellular signaling events seem to be essential in vessel formation at least during 
embryogenesis (Wang et al., 2006). Nrp-1 signaling is poorly understood, but recent 
findings suggest that Nrp-1 transduces biological signals via NIP (neuropilin interacting 
protein, GIPC) and GAIP (Gα interacting protein) leading to G-protein mediated signaling. 
GIPC binds to C-terminal three amino acids of Nrp-1. This complex formation has been 
shown to be essential for EC migration in vitro and angiogenesis in vivo (Wang et al., 
2006). Further, GIPC has been shown to bind to GAIP, a member of RGS (regulator of G-
protein signaling) family suggesting a link to G-protein mediated intracellular signaling 
events (De et al., 1998).  
Nrp-1 binds several VEGF family members: VEGF-A165, PlGF-2, VEGF-E, VEGF-
B167, VEGF-B186 after proteolytical activation of the protein, VEGF-C (Ober et al., 2004) 
and partially processed form of VEGF-D (Soker et al., 1998; Mäkinen et al., 1999; Migdal 
et al., 1998; Kärpänen et al., 2006a). Binding of several VEGFs is dependent on heparin, 
but in addition heparin may induce multimerization of the receptor, possibly altering its 
function (Fuh et al., 2000). Nrp-1 co-expression enhances VEGF-A165 binding to VEGFR-2 
(Soker et al., 1998) but the biological role of PlGF-2 binding remains unclear (Migdal et al., 
1998).  
 Several different splice forms are generated by alternative splicing of the Nrp-1 
gene, including naturally occurring soluble monomeric forms that function as natural 
inhibitors. Soluble Nrp-1 is expressed in heart, placenta and by some tumor cell lines 
(Gagnon et al., 2000). Soluble Nrp-1 dimer can partially restore the function of Nrp-1, 
indicating that receptor complexes can form between soluble and cell membrane bound 
receptors (Yamada et al., 2001). Accordingly, VEGFR-2 and Nrp-1 can form complexes 
via bridging with VEGF-A165 even when these two receptors are expressed by different 
cells (Soker et al., 2002) or when Nrp-1 is in soluble, dimeric form (Yamada et al., 2001). 
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Other molecules regulating blood vessel growth 
 
 VEGFR-3 has been suggested to be involved in blood vessel growth. VEGFR-3 
null embryos die on E9.5 due to disturbances in blood vessel development (Dumont et al., 
1998). VEGFR-3 is expressed on both blood and lymphatic vessel endothelium from E8 
onward, but its expression becomes mostly limited to lymphatic ECs in midgestation 
(Kaipainen et al., 1995). A subset of fenestrated capillary endothelial cells expresses 
VEGFR-3 also in adult (Partanen et al., 2000). Tumor blood vessels have been shown to 
express VEGFR-3 (Valtola et al., 1999). VEGFR-3 was also shown to be involved in 
hypoxia-driven angiogenesis in an in vitro model using embryonic bodies (Nilsson et al., 
2004).  
 Angiopoietins (Ang) have been shown to be involved in both blood vessel growth 
and stabilization (Holash et al., 1999), platelet-derived growth factors (PDGFs) participate 
in angiogenesis by regulating mural cell proliferation (Andrae et al., 2008) and recruitment 
and fibroblast growth factors have been shown to induce both angiogenesis and 
arteriogenesis (Murakami and Simons, 2008).  
 
Summary of blood vessel growth 
 
Formation of mature blood vessel network requires coordinated function of several 
growth factors and receptors (Figure 5). Growth factor expression proceeds in a stepwise 
manner. Briefly, Hif1-α and its downstream target VEGF-A are essential in the initiation of 
blood vessel growth. VEGF-induced nitric oxide (NO) production dilates pre-existing 
vessels, VEGF-A increases permeability and co-expression of Ang-2 induces sprouting of 
the ECs (Lobov et al., 2002). VEGF expression induced EC proliferation and migration 
forming immature vascular networks. Remodeling of the neovessels adjusts the vascular 
network to metabolic needs of the tissue. Ang-2 in the absence of VEGF leads to EC 
apoptosis (Lobov et al., 2002), while sustained flow and expression of PDGFs stimulate 
pericyte proliferation and attachment to ECs leading to stabilization of vessels. Ang-1 has 
been also suggested to be involved in stabilization of the vessels and signaling in the 
quiescent state (Holash et al., 1999). 
As briefly described, coordinated function of several growth factors are needed to 
produce mature, functional vessels. In angiogenic gene therapy approaches usually only 
one growth factor is over-expressed. Fortunately, once blood vessel growth is initiated 
mechanical factors largely regulate the maturation process (Rissanen et al., 2005) and for 
example VEGF-A is capable of up-regulating factors required in the subsequent steps. 
Endogenous vascular network pruning and maturation after cessation of the growth factor 
production may also help to produce functional, mature vessels with single growth factor 
gene therapy. 
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Figure 5. Blood vessel growth is a multi-step process. Coordinated function of different growth factors and 
mechanical factors produce a hierarchical, functional vascular network. Modified from Markkanen et al. 
Cardiovascular Research, 2005. 
GENE THERAPY FOR CARDIOVASCULAR DISEASES 
 
Cardiovascular diseases are challenging targets for gene therapy approaches. Ischemic 
disease is a complex process involving a large number of genes and environmental 
factors, possibly beginning early in the childhood. Several different treatment targets and 
approaches have been published since the concept of therapeutic angiogenesis was 
introduced (Svet-Moldavsky and Chimishkyan, 1977). Pathogenesis of the atherosclerotic 
process has been targeted by lowering blood cholesterol level, inhibiting harmful 
modification of blood lipids and several other approaches. Angiogenic gene therapy 
focuses on the treatment of the complications of the ischemic disease. Atherosclerosis 
occludes blood vessels, and in acute infarction blood flow is blocked completely. 
Neovessel growth is induced to grow blood vessels around the block in the artery and to 
improve delivery of oxygen and nutrients to the ischemic tissue.  
 Therapeutic approach has to be chosen according to the therapeutic goal. 
Treatment of familial hypercholesterolemia requires life-long production of the low density 
lipoprotein (LDL) receptor in the hepatic cells, while a week of growth factor production 
may be sufficient to jump start angiogenesis in the border of a myocardial infarction scar 
(Markkanen et al., 2005). 
Cardiomyocytes as a target for gene therapy 
 
 Fatty acid metabolism requires a continuous supply of oxygen and removal of 
waste products to avoid lactate metabolism and a drop in the pH level. Cardiac muscle is 
capable of endogenously adapting to low levels of oxygen. Altering the cardiomyocyte 
metabolism to make cells more resistant to ischemia may be a potential treatment method 
for myocardial ischemia, at least in combination with angiogenic approaches. Production 
of new vascular cells requires approximately 24h and growth of new blood vessels takes 
from days to weeks (Schaper and Ito, 1996), and therefore fast alterations in metabolism 
may provide the extra time cardiomyocytes need for the neovessels to recover the blood 
supply. Maintaining myocyte vitality is essential, as 70% of the cells need to be viable in a 
segment of myocardium for it to be able to regain contractile function (deSilva et al., 1992). 
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In addition, scattered viable myocytes within the infarction scar may be more detrimental 
than beneficial by initiating ventricular arrythmias (Rothman et al., 1997). 
 Cardiac remodeling after myocardial infarction leads to fibrous tissue 
accumulation, compensatory hypertrophy with inadequate accompanying angiogenesis 
and ultimately to heart failure (Pfeffer et al., 1991; Colucci, 1997). Inhibiting cardiomyocyte 
apoptosis and negative remodeling events may improve the clinical outcome of the 
patients with AMI.  
 
Blood vessel growth as a target for gene therapy 
  
Blood vessel growth is an endogenous response to ischemia. However, 
endogenous repair attempts often fall short and the need to develop therapeutic 
interventions persists. Endogenous collateral growth in humans occurs within a period of 
months to years, while ischemia often occurs acutely. Endogenous collateral artery growth 
can be sufficient to replace blood supply of one of the main coronary vessels at rest, but is 
usually not sufficient during stress. Despite new treatment methods for ischemic diseases, 
not all patients are suitable for conventional treatments. Diffuse coronary artery disease 
limits the possibilities of percutaneous coronary interventions (PCI) and some patients are 
in too poor general condition to undergo coronary bypass grafting. Angiogenic gene 
therapy is a promising new treatment for these patients.(Ylä-Herttuala et al., 2007)  
 Induction of blood vessel growth has two, partially separate goals: to increase 
capillary vessel area and density in the ischemic area and to grow arteries to supply blood 
into these capillaries (Markkanen et al., 2005). Angiogenesis in the ischemic area can 
improve transport of oxygen and nutrients to the ischemic area. Growth of these capillaries 
can be directly induced by over-production of angiogenic growth factors. Capillaries are 
thin-walled, and their ECs are separated from the tissue interstitium only by a 
discontinuous layer of pericytes and a thin basement membrane. In addition, capillaries 
are specialized to exchange molecules with the surrounding tissue. Capillary growth is 
therefore a feasible target of growth factor gene therapy. 
New capillaries need blood supply from up-stream arteries, and increase in local 
blood supply requires growth of the arteries supplying the area. Arterial endothelium is 
surrounded by a tight internal elastic lamina, layers of smooth muscle cells, an outer 
elastic membrane and an adventitia. Although many growth factors induce proliferation of 
smooth muscle cells, their delivery to correct microenvironment within the vessel wall 
poses a challenge. Further, unbalanced proliferation of the cells in the vessel wall may 
lead to obstruction of the vessel lumen rather than flow-increasing growth of the vessel 
caliber. Several studies including our own work, however, have reported collateral artery 
growth after growth factor delivery (Rissanen et al., 2003a). This may be due to 
hemodynamic alterations: increased total capillary vessel area downstream increases flow 
in the supplying arteries, leading to endogenous arteriogenesis stimulated by increased 
shear stress (Rissanen et al., 2005). 
 In addition to myocardial ischemia caused by atherosclerosis, therapeutic 
angiogenesis may provide a tool to treat pathologic cardiac hypertrophy and prevent 
cardiac failure. In pathologic hypertrophy initially beneficial adaptive process leads to 
ischemia due to imbalance in increases of capillaries and cardiomyocyte size (Tomanek, 
1990). This may be due to too rapid hypertrophy of the cardiomyocytes or by attenuated 
angiogenic responses in the pressure-overloaded heart (Choi et al., 2008). Eventually this 
imbalance leads to heart failure (Shiojima et al., 2005). 
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Safety issues in angiogenic gene therapy 
  
 Safety in adenoviral angiogenic gene therapy experiments consists of two main 
parts, the safety issues related to the viral construct and safety issues related to the 
transgene. Adenoviruses trigger both rapid innate and adaptive immune responses when 
viral particles are in contact with blood (St George, 2003). In addition, 98% of adenoviral 
genomes were associated with blood cells after in vivo gene transfer in humans. 
Interestingly, such interactions were not observed with mouse blood cells highlighting the 
possibility of species-specific responses (Lyons et al., 2006). Contact with 
reticuloendothelial system induces release and production of several proinflammatory 
cytokines possibly causing systemic responses (St George, 2003). However, in both 
experimental and clinical settings therapeutic adenoviral doses have been well tolerated. 
Toxicity associated with adenoviral vectors is dependent on the dose and route of 
administration. If adenoviral vector is delivered locally to a tissue permissive for adenoviral 
transduction, systemic spread and contact with blood cells can be significantly reduced 
(Baker et al., 2007). 
Adenoviral particles are eliminated from the blood stream within 3 minutes of i.v. 
administration (Seshidhar et al., 2003). Adenovirus does not integrate into the host DNA 
and transgene expression time is limited to a few weeks thus limiting the side effects of the 
therapeutic product. However, if foreign proteins are used, the protein itself may trigger the 
immunological responses. In case of VEGFs, the most relevant safety issues can be 
controlled by correct dosing, delivery method and expression time of the growth factor: 
vascular permeability leading to edema (discussed elsewhere), excessive blood vessel 
growth, stimulation of blood vessel in unwanted areas. Adenoviruses have natural tropism 
for liver, and systemic expression in a variety of tissues was reported after intravenous 
delivery (Hiltunen et al., 2000b). Physical targeting of the virus by selective delivery 
methods is therefore required to minimize the systemic effects (Simons et al., 2000; Ylä-
Herttuala and Alitalo, 2003). 
Too high local concentration or prolonged expression time of angiogenic growth 
factors may induce chaotic growth of blood vessels and formation of glomerular bodies, 
disorganized vascular structures (Schwarz et al., 2000; Lee et al., 2000). These may 
develop to hemangiomas, vascular tumors, or disturb tissue blood flow by either stealing 
blood from other areas or fail to deliver blood and nutrients to tissues due to slow and 
turbulent blood flow (Carmeliet, 2000). Natural pruning process of the vascular network 
limits the possibility of these side effects. Although expression level of growth factors is 
high after adenoviral delivery, expression time is limited. If excessive growth of blood 
vessels occurs in the initial phase, cessation of the growth factor production and 
distribution of blood flow according to the needs of the tissue allow the remodeling of the 
vascular network to meet the demand (Sho et al., 2001). Cessation of the VEGF 
production may also allow maturation of the vessels, as VEGF-A has recently been shown 
to prevent EC-pericyte interactions (Greenberg et al., 2008). 
Administration of VEGF protein has been shown to induce vasodilatation via 
VEGFR-2 (Li et al., 2002), and intracoronary delivery of large dose of VEGF recombinant 
protein induced severe hypotension in pigs (Hariawala et al., 1996), limiting the safe 
therapeutic dose. Transient tachycardia, hypotension and decreased cardiac output were 
observed in rats after i.v. administration (Yang et al., 1996). These side effects are likely 
avoided by local delivery and production of growth factors, resulting in much lower serum 
levels of growth factors. In addition, after adenoviral delivery protein production starts 
slowly and compensatory mechanisms may hamper these effects. 
Blood vessel growth is required for a tumor to grow beyond the diameter of 1-2 
mm (Carmeliet, 2005). Tumor cells are capable of producing a wide variety of angiogenic 
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growth factors. The local concentration of these factors determines a tumorigenic switch, a 
critical level of growth factor in the microenvironment to induce angiogenesis. Millions of 
microtumors form and are destroyed during a lifetime. Exogenous stimulation of 
angiogenic growth factor production may increase the systemic levels of growth factors 
and facilitate growth of these dormant tumors (Bergers and Benjamin, 2003).  
 Angiogenesis occurs also in atherosclerotic plaques, and the effect of exogenous 
growth factor delivery on the progression of the disease remains unclear (Khurana et al., 
2005). Growth factor production and neovessel formation have been shown to destabilize 
plaques making them vulnerable to rupture and thus increasing the risk of a 
tromboembolic event (Hayden and Tyagi, 2004). Thus increase in systemic levels of 
angiogenic factors could contribute to an increase in cardiovascular events. However, 
over-expression of VEGFs was not shown to be associated with increased atherosclerosis 
in mice (Leppanen et al., 2005) and no such side effects have been observed in clinical 
studies (Mäkinen et al., 2002).  
 Short half lives of VEGFs limit their systemic effects. As measured by ELISA, the 
half lives of VEGF-A and VEGF-D in the plasma are approximately 8 and 15 minutes, 
respectively. Growth factors are cleared form the circulation completely by 30 min after 
recombinant protein administration likely due to clearance by the liver, spleen and the 
kidneys (Veikkola et al., 2001). The production of the growth factors by the transduced 
cells is however continuous, and significant concentrations can be released to circulation 
in therapeutic approaches (Rissanen et al., 2003b). Growth factors differ in their solubility, 
which determines how easily they are transported from the transduced tissue to the 
systemic circulation. Therefore also matrix-binding properties of the growth factors can be 
exploited to control the spread of the therapeutic protein. 
 
LYMPHATIC SYSTEM  
 
Anatomy and function of lymphatic vessels 
 
Lymphatic vessels regulate tissue fluid balance by transporting proteins and 
extravasated fluid from the interstitial space. In addition, lymphatics transport inflammatory 
cells and antigens to lymph nodes and transport absorbed triglycerides from intestinal wall 
to blood circulation. Lymphatic vessels play an active role in the maintenance of fluid 
balance. Water and proteins are filtered to the interstitial space in the arterial end of the 
capillaries. Under normal conditions, the majority of the filtered fluid reenters the 
circulation in the postcapillary venules, and only a small portion of the fluid is removed via 
lymphatic capillaries. In pathological conditions when permeability of the capillaries in 
increased more fluid enters the interstitial space. Lymphatic vessels can increase their 
capacity by 3-4-fold, but if this capacity is surpassed fluid and protein accumulation leads 
to tissue edema (Guyton and Hall, 2000). 
Lymphatic vessels start as blind-ended capillaries. They have discontinuous 
basement membrane and have no pericyte coverage. Lymphatic ECs have loose 
intracellular connections and are attached to interstitial collagen and elastin via anchoring 
filaments. Via these, an increase in interstitial volume pulls open the interendothelial 
valves and expands the lymphatic lumen (Kärpänen and Alitalo, 2008). In this manner a 
combined increase in hydraulic conductivity and pressure gradient facilitates lymph 
formation. The collecting lymphatics have an intrinsically contractile smooth muscle layer 
as part of their vessel wall. Collecting lymphatic vessels unite to form larger collecting 
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trunks and finally ductus thoracicius, a lymphatic trunk that delivers lymph to the venous 
circulation (Guyton and Hall, 2000). Anastomoses between lymphatic vessels and veins 
have been shown to exist at least in the kidneys, adrenal glands and in the liver. 
Lymphaticovenous anastomoses also develop in several conditions where lymphatic flow 
is disturbed (Aalami et al., 2000). 
  
 
 
GROWTH OF LYMPHATIC VESSELS 
 
Formation of the lymphatic system 
 
Lymphatic vessels begin to develop after the initial blood vessels have formed. 
Endothelial cells in the anterior cardinal vein start to express lymphatic vessel hyaluronan 
receptor 1 (LYVE-1), and a few hours later expression of transcription factor prospero-
related homeobox 1 (Prox1) starts. Prox1 is required for formation of the lymphatic system 
(Wigle and Oliver, 1999) and for lymphatic differentiation of the ECs essential for further 
development of the lymphatic system (Wigle et al., 2002). Differentiating lymphatic ECs 
bud from the cardinal vein and migrate to form primitive lymph sacs in response to VEGF-
C expression (Kärkkäinen et al., 2004). Lymphatic vasculature forms from centrifugal 
sprouting from these primitive lymphatic structures (Hong et al., 2004). 
Lymphatic cell phenotype remains adjustable. Venous endothelial cells are 
capable of transdifferentiating into lymphatic cells (Hong et al., 2002; Petrova et al., 2002) 
and blood ECs are able to assume a lymphatic phenotype. Both of these processes are 
controlled by prox1 transcription factor activity which is required for maintenance of the 
lymphatic phenotype (Johnson et al., 2008). Separation of lymphatic and blood vascular 
networks is maintained by tyrosine kinase Syk and adaptor protein Slp76. Interestingly, 
these factors are not expressed on lymphatic endothelium and separation of these 
vascular beds may require presence of circulating blood cells (Abtahian et al., 2003). 
 Lymphatic vessel development continues during the postnatal period. Collecting 
lymphatic vessels both sprout to produce superficial lymphatic capillaries and mature to 
conducting lymphatic vessels by acquiring a smooth muscle cell layer. Lymphatic vessels 
remain dependent on VEGFR-3 activation for several weeks after birth after which 
lymphatic vessels become resistant to VEGFR-3 inhibition (Kärpänen et al., 2006b). 
Further hierarchical differentiation may also be dependent on flow in the lymphatic vessels 
(Ng et al., 2004). 
 
 
All vascular tissues excluding the brain contain also 
lymphatic vessels. In skeletal muscles, lymphatic 
vessels are mainly located in the connective tissue 
between muscle bundles (Figure 6). In the 
myocardium, lymphatic capillaries drain to 
collecting lymphatic vessels located mainly on the 
epicardial surface.  
 
Figure 6. Lymphatic vessels in the skeletal muscle are located 
in connective tissue between the muscle bundles. Vessels run 
both parallel and across the direction of the muscle fibers. 
LYVE-1 staining, magnification 200X, scale bar 100µm. 
Lähteenvuo et al., unpublished results. 
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Growth of lymphatic vessels in adult 
  
Endogenous stimuli induce lymphangiogenesis in chronic inflammation. Lymphatic 
vessel growth is observed in kidney transplant rejection, chronic airway inflammation and 
in psoriasis (Alitalo et al., 2005). Inflammation induces lymphangiogenesis via several 
mechanisms. Macrophages secrete lymphangiogenic growth factors VEGF-C and VEGF-
D and may even be able to transdifferentiate into lymphatic ECs. Proinflammatory 
cytokines such as nuclear factor kappa-B (NFκB) up-regulate VEGF-C that is able to 
induce lymphatic vessel growth in adult tissues (Watari et al., 2008). 
 Lymphangiogenesis also occurs side by side with endogenous angiogenesis at 
least in wound healing and in forming myocardial infarction scar (Paavonen et al., 2000; 
Ishikawa et al., 2007). Inhibition of lymphangiogenesis has been shown to inhibit and over-
expression of lymphatic growth factors to improve wound healing (Saaristo et al., 2006).  
 Lymphatic vessel growth in adult occurs mainly via sprouting from pre-existing 
lymphatic vessels (Paavonen et al., 2000). Lymphatic endothelial precursor cells have 
been shown to exist in peripheral blood (Salven et al., 2003) and to emerge in in vitro 
models (Kreuger et al., 2006), but their role in lymphatic neovessel growth in vivo has not 
yet been clearly demonstrated. In renal transplants lymphatic progenitor cells have been 
suggested to be incorporated into forming lymphatic vessels (Kerjaschki et al., 2006) while 
no incorporation of bone marrow derived precursors was observed in tumor xenografts 
(He et al., 2004). Also other cell types such as macrophages have been shown to 
incorporate into lymphatic vessels (Maruyama et al., 2005). 
 
MOLECULES REGULATING LYMPHATIC VESSEL GROWTH 
 
 
Vascular endothelial growth factor receptor-3 (VEGFR-3)  
  
In early development VEGFR-3 (Flt-4) is expressed by both lymphatic and blood 
vessel endothelial cells. During development its expression becomes restricted to the 
lymphatic capillary endothelium and some expression is detected in specialized 
fenestrated blood capillaries (Kaipainen et al., 1995; Partanen et al., 2000). VEGFR-3 
signaling is required for development and maintenance of lymphatic vessels during 
embryonic development and for two weeks after birth in mice (Kärpänen et al., 2006b). 
VEGFR-3 null mice die in utero due to malformations in the cardiovascular system 
(Dumont et al., 1998). Experiments in morpholino knock down tadpoles supports the role 
of VEGFR-3 in developmental lymphangiogenesis, although blood vascular malformations 
Many molecules connected to 
lymphatic vessel growth have been identified. 
The most important regulators are VEGFR-3 
and its ligands both during embryonic 
development and in adult tissues. Also Nrp-2 
has recently been identified as a regulator of 
lymphatic vessel growth (Figure 7). 
 
Figure 7. Vascular endothelial growth factors and their 
receptors regulating lymphatic vessel growth. 
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occur also in this model (Ny et al., 2008). VEGFR-3 is also expressed in the adult 
lymphatic endothelium, and VEGFR-3 stimulation is sufficient to induce 
lymphangiogenesis (Veikkola et al., 2001). 
 
Vascular endothelial growth factor-C (VEGF-C) 
 
 VEGFR-3 ligand VEGF-C was the first identified VEGFR-3 ligand and its 
expression pattern suggested a role in lymphatic vascular development (Joukov et al., 
1996; Kukk et al., 1996). VEGF-C null mice lack lymphatic vasculature and die on 
embryonic day 15 and lack of one VEGF-C allele results in lymphedema. VEGF-C is 
essential for the initial sprouting of differentiating lymphatic ECs during embryogenesis 
(Kärkkäinen et al., 2004). VEGF-C is produced as a full length protein, and further 
proteolytically processed by intracellular proprotein convertases furin, PC and PC7 and the 
secreted protein is further processed extracellularly by plasmin (Joukov et al., 1996; 
McColl et al., 2003; Siegfried et al., 2003). Proteolytic processing of VEGF-C increases its 
affinity to VEGFR-2 and during early embryonic development VEGF-C may induce its 
effects on cardiovascular development via VEGFR-2. Proteolytic processing also likely 
increases the angiogenic functions of VEGF-C in inflammatory situations and in tumor 
environment where proteolytic molecules are abundant. VEGF-C is expressed in multiple 
adult tissues, but the strongest expression is detected in the heart, placenta, skeletal 
muscle, ovary and small intestine (Joukov et al., 1996). 
 VEGF-C156S is an artificial VEGFR-3 specific ligand. Replacing the second of the 
eight cystine residues with a serine residue limits the binding of the growth factor solely to 
VEGFR-3 (Joukov et al., 1998). Its transgenic expression in the skin induces 
lymphangiogenesis but no induction of blood vessel growth (Veikkola et al., 2001). 
 
Vascular endothelial growth factor-D (VEGF-D) 
 
 VEGF-D is not required for lymphatic vessel development, as the only defect in 
Vegfd null mice is a slight reduction of lymphatic vessel density around the bronchioles 
(Baldwin et al., 2005). However, VEGF-D may amplify the effects of other 
lymphangiogenic molecules, as morpholino knockdown experiments in tadpoles suggest 
an effect on lymphatic EC sprouting and migration, but not on function of lymphatic 
vessels (Ny et al., 2008). VEGF-D is produced as a full length protein that binds 
preferentially to VEGFR-3. Proteolytic processing of VEGF-D by plasmin increases its 
affinity to VEGFR-2 and increases its angiogenic potency (McColl et al., 2007). However, 
even the processed form has a higher affinity towards VEGFR-3. VEGF-D is naturally 
expressed most tissues, but the highest expression is detected in the lungs and skin 
during embryogenesis (Yamada et al., 1997) and heart, lung, skeletal muscle, colon, and 
small intestine in the adult (Achen et al., 1998). Smooth muscle cells of human arteries 
contain large amounts of the unprocessed form of VEGF-D (Rutanen et al., 2003).  
The role of VEGF-D in adult remains unclear. Wide expression adult tissues, high 
conservation of the structure and in vivo processing of the protein suggest a biological role 
for VEGF-D and similarities of structure and function with VEGF-C further imply a role in 
lymphatic vessels. VEGF-D is involved in blood vessel growth and transgenic over-
expression of VEGF-D was shown to facilitate recovery after peripheral ischemia 
(Kärkkäinen et al., 2009). Over-expression of VEGF-D induces lymphatic vessel growth in 
the adult (Veikkola et al., 2001). The role of VEGF-D might be to induce lymphatic vessel 
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growth in inflammatory situations to alleviate edema. Macrophages present in inflamed 
tissues and in edematous angiogenic tissue produce VEGF-D (Watari et al., 2008). 
Therefore, lymphangiogesis induced by VEGFR-1 and VEGFR-2 ligands may be an 
indirect effect induced by macrophage recruitment (Murakami et al., 2008). Inflammation 
provides both a stimulus for macrophage recruitment and presence of proteases to 
activate the protein. VEGF-D expression has also been connected to lymphatic metastasis 
and leukocyte infiltration possibly connected to cancer angiogenesis (Bouma-ter Steege et 
al., 2004). Emphasizing the role of VEGF-D in cancer, transgenic over-expression has 
been shown to induce spontaneous tumor formation and to promote the growth of tumor 
xenografts (Kärkkäinen et al., 2009). 
 
Neuropilin-2 (Nrp-2) 
  
Nrp-2 is expressed in embryonic veins and later in lymphatic ECs. Nrp-2 null mice 
lack small lymphatic vessels and capillaries at birth but larger collecting lymphatic vessels 
developed normally and animals were not edematous (Yuan et al., 2002). Lymphatic 
vessel growth was rescued postnatally in surviving mice, but postnatally developed 
lymphatic vessels were abnormally patterned especially in the heart and in the intestine. 
Nrp-2 may therefore be required for sprouting of lymphatic capillaries from pre-existing 
lymphatic vessels.  
Nrp-2 expression is also detected in adult lymphatic vessels. Nrp-2 binds VEGF-C 
in a heparin-independent and VEGF-D in a heparin-dependent manner (Kärkkäinen et al., 
2001; Kärpänen et al., 2006a). Nrp-2 is capable of forming a complex with VEGFR-3 and 
is internalized with VEGFR-3 after VEGF-C and VEGF-D stimulation suggesting that it 
might modulate VEGFR-3 signaling (Kärpänen et al., 2006a). Nrp-2 inducess also 
migration of cultured lymphatic ECs (Kärpänen et al., 2006a).  
Also angiogenic factors VEGF-A145, VEGF-A165 and PlGF bind to Nrp-2 (Gluzman-
Poltorak et al., 2000; Neufeld et al., 2002). However, the biological role of this binding 
remains unclear, as the binding of VEGF-A165 to Nrp-2 does not induce internalization of 
Nrp-2 or interaction with VEGFR-2 (Kärpänen et al., 2006a). Furthermore, although Nrp-2 
is expressed in venous endothelium, veins developed normally in Nrp2- null mice (Yuan et 
al., 2002). 
 
Other molecules regulating lymphatic vessel growth 
 
 VEGFR-2 has been suggested to play a role in lymphangiogenesis. VEGFR-2 is 
expressed on collecting lymphatic vessels and in growing lymphatic capillaries (Jeltsch et 
al., 1997; Veikkola et al., 2001). Orf virus derived selective VEGFR-2 ligand VEGF-E has 
been shown to induce lymphatic vessel dilation and several publications have reported 
induction of lymphangiogenesis by VEGFR-2 ligand VEGF-A (Wirzenius et al., 2007). 
However, the role of inflammation, up-regulation of endogenous lymphangiogenic growth 
factors and edema has not fully been addressed. In embryonic bodies cultured in vitro 
VEGF-A did not induce differentiation of lymphatic ECs or lymphatic vessel sprouting, 
possibly due to lack of blood flow, vascular leakage and edema in this model (Kreuger et 
al., 2006). 
 Several integrins are also expressed in lymphatic ECs and function as ligands for 
lymphangiogenic growth factors. Integrin α 9β1 has been shown to bind VEGF-C and 
VEGF-D (Vlahakis et al., 2005) and integrin α5β1 participates in VEGFR-3 activation by a 
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VEGFR-3 specific ligand VEGF-C156S (Zhang et al., 2005). Integrin β1 stimulation by 
fibronectin and collagen has been shown to lead to tyrosine phosphorylation of VEGFR-3 
(Wang et al., 2001a). 
 Angiopoietin receptors Tie1 and Tie2 are expressed in lymphatic ECs. Tie2 
receptor has two known ligands, Ang-1 and Ang-2. Their functions differ in blood and 
lymphatic vessels. In lymphatic cells both ligands seem to have agonistic functions. Ang-2 
deficient mice have disorganized lymphatic vasculature and lymphatic vessel dysfunction 
(Gale et al., 2002). Ang-1 is capable of rescuing this phenotype and its over-expression 
has been shown to induce lymphatic vessel growth in adult tissues (Tammela et al., 
2005b). EphrinB2 has been shown to be involved in lymphatic vessel maturation. Deletion 
of PDZ binding site of EphrinB2 lead to formation of pericyte-covered lymphatic capillaries 
and disturbances in lymph flow (Mäkinen et al., 2005). 
 
LYMPHATIC VESSEL GROWTH AS A THERAPEUTICAL TARGET 
 
Lymphedema 
 
 Lymphedema is a chronic disturbance of lymph flow leading to progressive 
swelling of the affected tissues. In hereditary forms the underlying cause is a gene 
mutation leading to abnormal lymphatic vessel development (Kärkkäinen et al., 2000; 
Irrthum et al., 2000; Finegold et al., 2001). Radiotherapy, trauma or surgical damage to 
lymph vessels can lead to acquired lymphedema. 20-30% of surgically treated breast 
cancer patients who undergo axillary lymphnode evacuation suffer from lymphedema, and 
no efficient treatments are yet available for this condition. Induction of lymphatic vessel 
growth is therefore a promising approach for these patients. Promising results have been 
obtained in small animal models. (Tammela et al., 2007) 
 
Lymphatic vessels in reduction of edema 
 
 Lymphatic vessels regulate interstitial fluid and protein concentrations. In 
angiogenic gene therapy the most important side effect is an increase in vascular 
permeability, leakage of plasma proteins to interstitial space and subsequent edema. 
Edema in peripheral muscle compartments can lead to compartment syndrome and in 
myocardium to the accumulation of pericardial fluid and even tamponation of the heart. 
Endogenous blood vessel growth in inflammation, wound healing and in healing 
myocardial infarction scars is accompanied by lymphangiogenesis (Paavonen et al., 2000; 
Ishikawa et al., 2007).  Promoting lymphatic vessel growth may therefore help to balance 
the blood and lymphatic vessel growth responses and reduce the side effects of 
angiogenic gene therapies. 
 
Safety issues concerning lymphangiogenic gene therapy 
 
 Lymphatic vessels are the most important route of metastasis for many solid 
tumors (Achen and Stacker, 2008). Many tumors produce lymphangiogenic growth factors 
such as VEGF-C and VEGF-D, and blocking VEGFR-3 has been shown to inhibit 
lymphatic vessel growth in tumors and to prevent metastasis (He et al., 2002). Recently 
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lymphangiogenesis has been shown to occur in sentinel lymph nodes before tumor cells 
have metastasized suggesting that secreted lymphangiogenic factors reach 
concentrations sufficient to induce lymphatic vessel growth (Das and Skobe, 2008).  
 Over-expression of lymphatic growth factors may promote subclinical microtumor 
metastasis (Achen and Stacker, 2008). Processed forms of VEGF-C and VEGF-D are 
readily soluble and were secreted to circulation after adenoviral delivery. Transgenic over-
expression of VEGF-D was shown to promote tumor growth in mice (Kärkkäinen et al., 
2009). While no promotion of spontaneous tumor growth has been reported after delivery 
of lymphangiogenic factors, systemic concentration of these factors, local delivery 
methods and limiting expression to targeted cell type are important considerations in 
lymphangiogenic gene therapy.  
 
ANIMAL MODELS IN GENE THERAPY RESEARCH 
 
 Studies on growth factor biology and receptor kinetics have been largely done in 
vitro. However, animal models are required to further elucidate their biological function. 
Biological responses often require interplay between several cell types, and possibly 
components of the extracellular environment. Such interactions, although often possible to 
reproduce also in in vitro settings, can be difficult to predict without in vivo data. Further, 
biodistribution of therapeutic substances and systemic effects such as effects on blood 
pressure can only be studied in vivo. Effects of growth factors on different diseases can 
only be performed in animal models, and data obtained from transgenic animals is 
essential to study their biological relevance. Use of animal models is thus essential to 
develop new therapies. 
 Molecules may have slightly different functions in different species, and for 
example different receptor binding profiles have been demonstrated for human and mouse 
VEGF-D (Baldwin et al., 2001). Mechanisms of blood vessel growth vary between small 
and large animals. Angiogenesis in the skeletal muscles in response to VEGF is mainly 
enlargement in rabbits (Rissanen et al., 2003a) but increase in vessel density in mice 
(Kholova et al., 2007). Rabbit collaterals can increase in diameter from 50µm up to 
400µm, while collaterals in mice only increase their diameter 2.5-fold and acquire only 1-2 
layers of smooth muscle cells (Scholz et al., 2000). Large animal models that resemble 
human as closely as possible are thus invaluable in increasing safety before clinical trials 
are initiated. VEGFs in general are highly conserved but differences between species 
exist. For example, comparisons of mouse, rabbit and pig VEGF-A and VEGFR-2 
homologies are presented in tables 1 and 2. 
 
Table 1. Homologies as compared to human VEGF-A (NM_001025366.1) 
Species Gene ID Query coverage Max identity 
Mouse (mus musculus) NT_039649.7 92% 97% 
Rabbit (oryctolagus cuniculus) AY196796.1 9% 91% 
Pig (sus scrofa) CT009664.17 93% 100% 
 
Table 2. Homologies as compared to human VEGFR-2 (NM_002253.2) 
Species Gene ID Query coverage Max identity 
Mouse (mus musculus) NM_010612.2 83% 82% 
Rabbit (oryctolagus cuniculus) AB017155.1 8% 88% 
Pig (sus scrofa) EU14326 99% 90% 
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The pig genome is only partially known, and relevant comparisons to all VEGFs 
and receptors cannot yet be made based on published data. However, high homologies of 
the known members of the VEGF family suggest that pig is a relevant model to study the 
functions of human growth factors. The metabolism and ability to tolerate toxins varies 
between species, and thus doses of therapeutic agents cannot be directly extrapolated to 
humans from rodents. Delivery methods effect the local concentration of therapeutic agent 
achieved, and methods relevant for clinical applications may be difficult to reproduce in 
small animal models. Finally, methods to study and monitor the effects of therapies need 
to be validated in animal models prior to clinical use. 
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AIMS OF THE STUDY 
 
The aim of this study was to develop a safe and efficient angiogenic gene therapy 
approach for the treatment of myocardial and peripheral ischemia. The goal was to find the 
most efficient VEGF family growth factor for angiogenic and lymphangiogenic therapies 
and to minimize the side effects. Clinical applications as a target, animal models, gene 
delivery methods and end point measurements were chosen to best reflect the clinical 
potency of the growth factor studied.  
 
The individual aims of the original publications were as follows: 
 
I 
The aim of this study was to compare different VEGFs side by side to choose 
optimal growth factors for the treatment of ischemia. Vascular endothelial growth 
factors mediate angiogenesis via VEGFR-2 and lymphangiogenesis via VEGFR-3 
while the role of VEGFR-1 remains unclear. Experiments studying the effects of 
different VEGFs have been performed in various in vivo and in vitro systems and 
in different species complicating the interpretation of their relative contributions to 
these effects. Direct comparison of angiogenic and lymphangiogenic properties 
and side effects in the same animal model using the same dose and route of 
delivery would allow in vivo profiling of VEGFs for therapeutic applications. 
 
II 
The aim of the second part of the study was to find optimal vector and dose of 
AdVEGF-D∆N∆C for angiogenic gene therapy in the myocardium. The goal was to 
induce neovessel growth in normal pig myocardium and to increase blood flow in 
the treated area. Also the safety and feasibility of this approach was assessed. 
 
III 
The aim of the third study was to explore the angiogenic potency and mechanism 
of the different VEGFR-1 ligands in both normoxic and ischemic skeletal muscles 
and in myocardium. Different aspects of myocardial infarction scar healing, 
apoptosis, cell proliferation and metabolic effects were addressed. Both rabbit and 
pig tissues were studied to reduce the possibility of species-specific functions of 
human growth factors.  
 
IV 
The aim of the fourth part of this study was to develop a combination gene therapy 
to minimize the side effects of angiogenic gene therapy by simultaneously 
inducing lymphatic vessel growth. The aim was also to elucidate the role of 
lymphatic vessel growth in the resolution of edema in the endogenous angiogenic 
response to ischemia.  
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METHODS 
 
ANIMAL MODELS 
 
 Gene transfers (GT) were done both to normoxic and ischemic rabbit skeletal 
muscles, normoxic rabbit heart, normoxic pig skeletal muscles and both normoxic and 
ischemic pig heart. Normoxic tissues were used for comparisons of different growth factors 
and mechanistic studies to avoid interference from endogenously up-regulated growth 
factors and receptors. Therapeutic potential of the most efficient growth factors were 
assessed in ischemia models. All animal experiments were approved by the Experimental 
Animal Committee, University of Kuopio. 
Rabbit hind limb ischemia model (I, III) 
 
Rabbit model of hind limb ischemia was used to study the angiogenic potency of 
VEGFs in peripheral muscles. Ischemia was induced by excising the superficial femoral 
artery. Re-entry branches for collaterals growing from the lateral circumflex and deep 
femoral arteries were ligated to limit the collateral growth to internal iliac artery (Rissanen 
et al., 2003a). In original publication III, one more re-entry branch from the lateral side of 
the knee was ligated to induce ischemia also in the distal thigh.  
 
Pig model of acute myocardial ischemia (III) 
 
 Myocardial ischemia was induced in domestic pigs by occluding the left anterior 
descending coronary artery (LAD) using a VortX-18 occlusion coil (Boston Scientific). 
Coronary vasculature was first visualized by angiography via a 7F catheter and a platinum 
occlusion coil was placed in the LAD vessel. Complete occlusion of the vessel was 
confirmed by angiography, movement defect in the anterior wall of the left ventricle by 
intracardiac ultrasound imaging (Acunav, Acuson Sequioia, Siemens) and by ECG 
changes. Infarction was allowed to stabilize for 30min before gene transfer. 
 
GENE TRANSFER METHODS 
 
 First generation replication deficient serotype 5 adenoviruses were used as gene 
transfer vectors. Adenoviruses expressing LacZ reporter gene, VEGF-A165, PlGF-2, VEGF-
B167, VEGF-B186, VEGF-E, VEGF-Cfull, VEGF-C156S, VEGF-D∆N∆C, VEGF-Dfull, soluble (s) 
VEGFR-1, sVEGF-2 and sNrp-1 under CMV promoter were used. The functionality of viral 
constructs was confirmed by RT-PCR, Western blot, ELISA, immunohistochemistry and 
confirmation of biological activity as presented in table 3. Virus dosing and delivery for 
VEGFs is presented in table 4.  
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Table 3. Functionality of viral constructs. 
construct method reference 
AdLacZ X-gal staining for Β-galactosidase  (Vajanto et al., 2002) 
AdVEGF-A RT-PCR 
Western blot 
ELISA 
Immunohistochemistry 
Biological activity 
(Bhardwaj et al., 2003) 
(Hiltunen et al., 2000a) 
(Vajanto et al., 2002; Viita et al., 
2008) 
(Bhardwaj et al., 2003) 
(Vajanto et al., 2002) 
AdVEGF-B167 RT-PCR 
Western blot 
ELISA 
Immunohistochemistry 
Biological activity 
(Bhardwaj et al., 2003) 
Dijkstra M., unpublished 
(Leppanen et al., 2005) 
(Bhardwaj et al., 2003) 
(Bhardwaj et al., 2003) 
AdVEGF-B186 Western blot 
Immunohistochemistry 
Dijkstra M., unpublished 
Lähteenvuo J., unpublished 
AdPlGF RT-PCR 
ELISA 
Biological activity 
(Viita et al., 2008) 
(Viita et al., 2008) 
(Roy et al., 2005) 
AdVEGF-Cfull RT-PCR 
Western blot 
 
ELISA 
Immunohistochemistry 
Biological activity 
(Bhardwaj et al., 2003) 
(Hiltunen et al., 2000a; Saaristo et 
al., 2002) 
(Leppanen et al., 2005) 
(Bhardwaj et al., 2003) 
(Saaristo et al., 2002) 
AdVEGF-C156S Western blot 
Biological activity 
(Saaristo et al., 2002) 
(Saaristo et al., 2002) 
AdVEGF-
D∆N∆C 
RT-PCR 
Western blot 
ELISA 
Immunohistochemistry 
Biological activity 
(Bhardwaj et al., 2003) 
Jauhiainen S., unpublished 
(Leppanen et al., 2005) 
(Bhardwaj et al., 2003) 
(Bhardwaj et al., 2003) 
AdVEGF-Dfull RT-PCR 
Western blot 
Immunohistochemistry 
Biological activity 
(Bhardwaj et al., 2003) 
(McColl et al., 2007) 
(Bhardwaj et al., 2003) 
(Bhardwaj et al., 2003) 
AdVEGF-E Western blot 
ELISA 
(Zheng et al., 2007) 
(Zheng et al., 2007) 
AdsVEGFR-1 RT-PCR 
Western blot 
ELISA 
Biological activity 
(Sallinen et al., 2009) 
(Sallinen et al., 2009) 
(Sallinen et al., 2009) 
(Roy et al., 2005) (Sallinen et al., 
2009) 
AdsVEGFR-2 RT-PCR 
Western blot 
ELISA 
Biological activity 
(Sallinen et al., 2009) 
(Sallinen et al., 2009) 
(Sallinen et al., 2009) 
(Roy et al., 2005; Sallinen et al., 
2009) 
AdsNrp-1 Western blot Jauhiainen S., unpublished 
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Table 4. Tissues, delivery methods, virus concentrations in viral particles (vp), total doses and injection volumes 
used in gene transfer experiments. 
 
For soluble receptor blocking experiments (III), larger virus concentrations were used to 
achieve 2-3 fold over-expression of the soluble receptor as compared to the growth factor 
studied (table 5). 
 
Table 5. Tissues, total doses of viruses encoding growth factors and injection volumes used in soluble receptor 
gene transfer experiments. 
Tissue Growth factor (total 
dose) 
Soluble receptor 
(total dose) 
volume 
Rabbit skeletal 
muscle 
1x1011vp 3x1011vp 1ml 
Normal pig heart 2x1012vp 4x1012vp 2ml 
Ischemic pig heart 1x1012vp 2-3x1012vp 2ml 
 
 To study the role of nitric oxide, L-NAME (Lω-Nitro-L-arginine methyl ester, 
Sigma) was administered twice a day (50mg/kg) p.o. for the duration of the experiment to 
a subset of animals. 
 
ASSESSMENT OF BLOOD VESSEL GROWTH 
 
Histology (I, II, III, IV) 
 
 Tissues were perfusion fixed with 1%PFA in citrate buffer (pH 3.5). Tissue 
samples were further immersion fixed in 4%PFA sucrose, embedded in paraffin and cut to 
7µm sections. Immunohistochemical stainings were performed to identify cell types, vessel 
structures, growth factors, receptors and components of intracellular signaling cascades. 
Avidin-biotin-HRP system with 3’-5’-diaminobenzidine (DAB, Zymed) and alkaline 
phosphatase system (Vector Laboratories) with Vector Blue (Vector laboratories) were 
used as color substrates. Tyramide amplification system (TSA-kit, NEN Lifescience) was 
used for VEGFR-2 and αvβ3 antibodies. Antibodies used are presented in table 6.  
 
 
Species tissue Delivery method Virus 
concentration 
Total 
dose 
volume 
rabbit skeletal 
muscle 
Intramuscular (i.m.) 
injection (25G needle) 
1x1011vp/ml 1x1011vp 10x100µl 
(1ml) 
rabbit normal 
heart 
Intramyocardial 
Injection 
1x1012vp/ml 5x1011vp 5x100µl 
pig skeletal 
muscle 
Intramuscular injection 
(20G needle) 
1x1011vp/ml 1x1012vp 10x1ml 
(10ml) 
pig normal 
heart 
Catheter-mediated 
intramyocardial 
Injection 
1x1012vp/ml 2x1012vp 10x200µl 
(2ml) 
pig ischemic 
heart 
Catheter-mediated 
intramyocardial 
Injection 
5x1011vp/ml 1x1012vp 10x200µl 
(2ml) 
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Table 6. Primary antibodies.  
Structure stained Antibody Manufacturer publication 
Endothelial cells 
(rabbit) 
CD31 DAKO I, III, IV 
Endothelial cells 
(pig) 
Pecam-1 Santa Cruz 
biotechnology 
III, IV, unpublished 
results 
Smooth muscle 
cells 
α-SMA (1A4) Sigma Adrich I, II, III, IV 
Lymphatic 
endothelial cells 
LYVE-1 R&D systems IV, unpublished 
results 
Proliferating cells BrdU (Bu20a) DAKO I, IV 
Proliferating cells PCNA Promega III 
Apoptotic cells TUNEL Chemicon III, IV 
VEGF-A VEGF (C-1) Santa Cruz 
biotechnology 
II, unpublished 
results 
VEGFR-2 Flk-1 Santa Cruz 
biotechnology 
I 
Integrin αvβ3 αvβ3 Biogenesis I 
Nrp-1 Nrp-1 (C-19) Santa Cruz 
biotechnology 
III 
GIPC GIPC (N-19) Santa Cruz 
biotechnology 
III 
GAIP GAIP (N-17) Santa Cruz 
biotechnology 
III 
Transduced cells β-galactosidase (β-gal) Promega Unpublished results 
Blood and lymphatic vessel measurements (I, II, III, IV) 
 
Mean blood vessel area (µm2) was measured from CD31 immunostained sections 
of rabbit skeletal muscles at 200X magnification. Pig tissues were stained with Pecam-1 
antibody and vessels from normal myocardium were analyzed at 200X magnification and 
the infarction edge samples were analyzed at 100X magnification. Lymphatic vessels were 
measured from CD31+α-SMA stained sections (I) or from LYVE-1 stained sections (IV and 
unpublished results) at 100X magnification. All measurements were performed with 
AnalySIS software (Soft Imaging System) in a blinded manner from 5-10 different 
randomly selected fields from each section. Means of the measurements were reported. 
 
Microspheres (I, II, III) 
 
 Fluorescent microsphere particles were used to measure tissue perfusion. Red 
fluorescent microspheres (1x106 in rabbits, 5x106 in pigs) were injected into the left 
ventricle and samples were collected from transduced and control tissues. Tissue samples 
were lysated in ethanol-potassium hydroxide solution (48h in +60C˚) and microspheres 
were isolated according to manufacturer’s instructions. 10 000 yellow-green microspheres 
were added to each sample as a reference in hind limb perfusion measurements. In 
myocardium, red microspheres were injected at rest, and pharmacological stress was 
induced using dobutamine infusion. Dobutamine infusion was gradually increased from 
5µg/kg until heart rate reached 200 beats per minute. Yellow-green microspheres were 
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then injected to measure perfusion during stress. Results were expressed as a ratio 
between transduced and control samples. 
 
Angiography (III) 
 
 Angiography was used to visualize collateral growth in hind limb and in 
myocardium. Digital subtraction angiography of the rabbit hind limbs was performed before 
sacrifice. Last image before venous filling was observed and chosen for analysis. 
Coronary angiographies were done in vivo before induction of AMI, and to confirm 
complete closure of the LAD, and ex vivo after the animals were sacrificed. Angiographies 
were performed with Siemens Siremobil (Siemens, Germany) using a 7F AR2 catheter 
(Cordis) and Gadolinium contrast agent.  
 
Ultrasound imaging and ejection fraction (II, III) 
 
 In normoxic myocardium, pericardial effusion was visualized from long axis 
projections with a 3V2c transducer (Acuson Sequoia, Siemens). Perfusion was assessed 
using myocardial contrast echocardiography. Contrast agent (2x108 bubbles/ml, SonoVue, 
Bracco) was injected via the ear vein, bubbles were destructed with high energy Doppler 
wave, and short axis view images were recorded from the mid-papillary level at the time of 
maximal refilling during systole. 
In ischemic myocardium, echocardiography was performed at the baseline, after 
AMI and before sacrifice with Acunav catheter inserted into the right atrium. Longitudinal 
2-chamber views are shown to visualize pericardial effusion six days after the gene 
transfer.  Cardiac ultrasound imaging was performed by using intracardiac ultrasound 
transducer (Acunav®, Acuson Sequoia, Siemens). Ejection fraction was measured from 
longitudinal two-chamber views using Acuson software (modified Simpsons formula). Two 
measurements from two different ultrasound recordings were done when possible. 
CEU perfusion measurement was done in skeletal muscle as described (Rissanen 
et al., 2003b) after a  bolus injection of a second generation contrast agent (2x108 
bubbles/ml, mean diameter 2.5 µm, SonoVue, Bracco, Italy) via the ear vein. 
  
PROTEIN ANALYSES 
 
Immunoprecipitation and Western blot (III) 
 
 Immunoprecipitation was performed to study ligand binding and receptor 
activation of Nrp-1. Protein lysates from transduced myocardium were incubated for 8h 
with Nrp-1 antibody (C-19, Santa Cruz biotechnology), protein A sepharose beads 
(Amersham Biosciences) were added and samples were incubated in +4C over night. 
Sepharose beads were then carefully washed with 0.2% Tween 20 in PBS and 
electrophoresis was performed. Western blot analyses were then performed with VEGF-B 
antibody (MAB 3373, R&D biosystems) to confirm ligand binding and with GIPC antibody 
(N-19, Santa Cruz biotechnology) to show receptor activation. GAIP (N-17, Santa Cruz 
biotechnology) expression was studied from native protein lysates with Western blot.   
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ELISA (II) 
 
 Enzyme linked immuno sorbent assay (ELISA) was used to measure local and 
systemic protein concentration after intramyocardial gene transfers. Proteins were isolated 
from snap frozen tissue samples using T-Per protein isolation buffer (Pierce), protease 
inhibitor was added (11697498, Roche) and total protein concentration of the samples 
were measured. ELISA kits for VEGF-A (DVE00) and VEGF-D (DVED00) (R&D 
biosystems) were used according to manufacturer’s instructions.  
 
VASCULAR PERMEABILITY 
 
Modified Miles assay (I, II, III, IV) 
 
 Vascular permeability of plasma proteins was measured by modified Miles assay. 
Evans blue dye (E2129, Sigma) was diluted to saline (30mg/ml, 1ml/kg) and injected 
intravenously 30 minutes before sacrifice. Evans blue binds to plasma proteins. Animals 
were perfusion fixed with 1%PFA in citrate buffer, pH 3.5 to clear remaining dye from 
blood vessels and to enhance dye binding to the tissues. Samples were incubated in 
formamide for 48 hours in +60C˚ to extract the dye from tissue samples and the amount of 
Evans blue was quantified with spectrophotometer at 610nm. Results were expressed as 
ratios between treated samples and intact controls. 
  
Magnetic resonance imaging (I) 
 
 Magnetic resonance imaging (MRI) was performed six days after the gene transfer 
to assess edema in the transduced rabbit skeletal muscles. Imaging was performed with a 
Varian UNITYinova (Varian Inc.) imaging console interfaced to a 4.7T horizontal magnet 
(Magnex Scientific Ltd.) Data were aquired 3min after gadodiamide contrast agent 
(Omniscan, Nycomed) with a custom built surface coil using a 3D flow compensated T2* 
weighted gradient echo sequence (FOV 6x8x6cm, matrix 256x128x64, tr=25ms, te=80ms) 
(Rissanen et al., 2003a). 
 
CELL CULTURE EXPERIMENTS (III) 
 
bEnd3 cells (ATCC) were cultured in high glucose DMEM (Gibco) supplemented 
with 10% FCS. Murine HL-1 cardiomyocyte cell line was kindly provided by Dr. W.C. 
Claycomb (Louisiana State University Medical Center)(4) and were cultured in Claycomb 
medium (JRH Biosciences Ltd.) supplemented with 10% FCS according to the instructions 
of Dr. Claycomb. mVEGF-B186, mVEGF-B167, mPlGF2 and sVEGFR1 were purchased 
from R&D systems (Minneapolis, MN). For the treatment of HL-1 and bEnd3 cells with 
VEGF-B or PlGF2, cells were starved in Claycomb medium containing 0.5% FCS for 4 h 
followed by addition of 100 ng/ml of the growth factors, or 1 µg/ml of sVEGFR1, and 
further incubated for 20-25 h. For experiments with conditioned media, the media from 
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growth factor treated bEnd3 cells was transferred to pre-starved HL-1 cells, and the HL-1 
cells were further incubated for 8h. Total RNA fractions were isolated, reverse transcribed 
and analyzed by real-time RT-PCR. All experiments were performed in triplicates, and 
were repeated three times. Primers for the analyzed genes are shown below (Table 7).  
 
Table 7. Primer sequences. All sequences are written 5’ 3’ 
 Fwd primer Rev primer 
mL19 GGTGACCTGGATGAGAAGGA TTCAGCTTGTGGATGTGCTC 
mFatp1  TCAATGTACCAGGAATTACAGAAGG GAGTGAGAAGTCGCCTGCAC 
mFatp4 GCAAGTCCCATCAGCAACTG  GGGGGAAATCACAGCTTCTC 
ssFatp4 TGGTCCGTGTCAACGAGG GGTGGACACGTTCTCGCC 
ssBeta-Actin ATGGAATCCTGCGGCATC CTTGCTGATCCACATCTGC 
 
Expression levels in cultured cells were normalized to the expression of mL19, whereas 
beta-actin was used as normalization gene for pig samples. For detection of Mouse BH3-
only genes (Bik1, Bmf1 and Bad1), Qiagen QuantiTect specific primers were used 
(Qiagen, Germany). m, Mouse; ss, Sus scrofa. 
 
STATISTICAL ANALYSES 
  
 Results are expressed as mean ±SEM. Statistical significance was evaluated 
using one-way ANOVA or Kruskal-Wallis followed by Mann-Whitney U test where 
appropriate in original publications I and II. In original publication III and unpublished work, 
statistical significance was evaluated using Linear Mixed Models (SPSS version 14.0) 
which is based on generalized estimating equations (GEE) or by ANOVA followed by 
Students t-test. P<0.05 (marked * in the figures) was considered statistically significant. 
Symbols ** and *** were used for significances of <0.01 and <0.001, respectively. 
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RESULTS AND DISCUSSION 
 
 
 Selected results from the original publications and unpublished data are 
presented. New viral constructs, staining methods and slowly accumulating data from 
experimental animal work has enabled new analyses and comparisons that were not 
available at the time of publication of the original articles. Therefore, the data presented 
does not follow the order of the original publications. For published data, the number of 
original publication is indicated in the figure legend. 
EFFICACY OF ADENOVIRAL GENE TRANSFER IN SKELETAL MUSCLE AND 
MYOCARDIUM 
 
 AdLacZ marker gene was used as a negative control for all gene transfer 
experiments. Transduction efficiencies were studied from β -galactosidase (β-gal) stained 
tissue sections (Figure 8). In skeletal muscles β-gal positive nuclei were observed both in 
the connective tissue between the muscle bundles and in the skeletal myocytes. 
Transduction efficiency was quite low (only a few percent of the cells), but positive nuclei 
were found thoughout the transduced muscle. Only occasional positive ECs were 
observed (a). In myocardium most of the transduced cells were cardiomyocytes (b). 
Approximately 50% of the cardiomyocytes were β-gal positive in the vicinity of the needle 
tracks. Transduction efficiency was higher on the epicardial side, forming a triangular 
pattern extending towards the epicardial surface from the injection site.  
 
Figure 8. β -gal staining (blue) for AdLacZ transduced cells six days after the gene transfer in rabbit skeletal 
muscle (a) and pig myocardium (b), magnification 100X, scale bar 200µm. Unpublished results. 
 
 Adenoviral transduction is dependent on the presence of specific molecules 
required for virus entry, mainly CAR receptor expression on the cell surface (Bergelson et 
al., 1997). Mechanical factors control the spread of the virus. Local virus concentration, 
rather than total viral dose, is more vital for the transduction efficiency. Physical qualities of 
the target tissue also play a role.  Intramyocardial pressure is higher in the endocardium 
(Katz, 2005), and the pressure gradient across the myocardial wall may push the virus 
towards the epicardium. Cardiomyocytes are tightly attached to one another and no large 
extracellular spaces exist. This may limit the local spread of the virus. In skeletal muscles, 
loose connective tissue separates skeletal muscle bundles forming a route for wider 
spread of the virus. 
 ECs are the target of angiogenic gene therapy, but in neither tissue environment 
are the endothelial cells transduced efficiently. This mimics growth factor production in 
endogenous angiogenesis, where cells in the hypoxic area secrete VEGF to stimulate 
directed blood vessel growth (Shweiki et al., 1992). The growth factor gradient is essential 
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for migration of ECs (Gerhardt et al., 2003; Barkefors et al., 2008), and growth factor 
production in the ECs may lead to formation of glomerular structures due to lack of 
directional stimulus. The lack of EC transduction may also limit the systemic spread of the 
growth factor. Transduced cells secrete the growth factors, and as ECs form the interface 
between local tissue environment and systemic circulation, lack of EC transduction may 
limit the systemic concentrations of the transduced growth factors. Epicardial spread of the 
virus on the other hand may increase the side effects. Epicardial cells are readily 
transduced, and production of angiogenic factors may lead to growth of aberrant blood 
vessels in the connective tissue, possible leading to the accumulation of pericardial 
effusion.  
 
Biodistribution 
 
Biodistribution of the adenoviral vector was studied from AdLacZ transduced 
animals (Figure 9). High transduction efficiency was achieved in the myocardium (a). A 
few transduced, β-gal positive cells were found from the spleen (c), lung (d) and a single 
positive cell also from the connective tissue in the ovary (f). No positive cells were 
observed in the liver (b) or in the kidneys (e). 
 
Figure 9. β -galactosidase staining for AdLacZ transduced cells in pig tissues, magnification 200X, scale bar 
100µm. Single β-galactosidase positive nuclei are shown in higher magnification in the inserts in figures c, d and 
f. Unpublishd results. 
 
 Biodistridution of the therapeutic protein was assessed from the pigs that received 
intramyocardial AdVEGF-A or AdVEGF-D∆N∆C GT (Figure 10). ELISA analysis showed 
high protein expression in the transduced myocardium in AdVEGF-D∆N∆C transduced 
animals (a) and human VEGF-D was also detected in the plasma six days after the GT (b). 
In AdVEGF-A transduced tissues no elevated VEGF-D protein levels were detected (b). 
ELISA analysis of the safety tissues revealed protein levels barely above the detection 
limit in some of the liver and spleen samples (data not shown).  
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Figure 10. VEGF-D concentrations (pg/mg of total protein) as measured by ELISA in transduced tissues 6 days 
after the GT (a) and in plasma (pg/ml of plasma) 6 days after the GT (b). From original publication II. 
 
Biodistribution of the adenoviral constructs consists of two entities, the spread of the viral 
vector shortly after the GT and the spread of the therapeutic protein. Only a few β -gal 
positive cells were found in the safety tissues analyzed indicating that local gene transfer 
reduces systemic spread of the virus (Hiltunen et al., 2000b). Growth factors are secreted 
from the transduced cells, and physical properties of the growth factors govern the 
distribution of the protein. AdVEGF-A165 binds to cell surfaces, whereas VEGF-B186 and 
VEGF-D∆N∆C are readily soluble. Low levels of VEGF-D protein detected in liver and spleen 
samples may therefore be due to the high blood content of these tissues, not local protein 
production in these tissues. Perfused tissue samples would shed more light on this issue. 
 
GROWTH OF BLOOD VESSELS IN MYOCARDIUM AND SKELETAL MUSCLE 
 
VEGFR-2 ligands induce blood vessel growth in skeletal muscle 
 
Capillary size, number and morphology were studied from CD31 stained skeletal 
muscle sections. Negative control AdLacZ did not alter capillary size or morphology (a). 
VEGFR-1 ligand AdPlGF induced angiogenesis (b) while AdVEGF-B167 (c) and AdVEGF-
B186 (d) were inefficient. VEGFR-2 ligands AdVEGF-A (e), AdVEGF-D∆N∆C (f) and 
AdVEGF-E (g) induced capillary growth. VEGFR-3 ligands AdVEGF-Cfull (h), AdVEGF-
C156S (i) and AdVEGF-Dfull (j) did not induce blood vessel growth (Figure 11). Several 
VEGFs bind to more than one receptor. VEGF-A binds to both VEGFR-1 and VEGFR-2 
and both full and ∆N∆C isoforms of VEGF-C and VEGF-D bind to VEGFR-2 and VEGFR-
3. Growth factors are grouped in the figure based on their main biological responses. 
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Figure 11. Transduced rabbit skeletal muscles 6 days after the GT. CD31 staining (brown) for endothelial cells, 
magnification 200X, scale bar 100µm. From original publications I, III and unpublished results. 
 
Quantification of blood vessel growth showed an increase in mean capillary area 
after the GT of VEGFR-2 ligands and after the AdPlGF GT (figure 12). VEGFR-3 ligands 
or AdVEGF-B167 and AdVEGF-B186 did not significantly increase mean capillary area. 
AdVEGF-D∆N∆C was the most potent inducer of angiogenesis increasing the mean capillary 
area 14-fold as compared to AdLacZ (Figure 12a). Capillary number was increased only 
after AdVEGF-A GT while other growth factors did not significantly increase mean capillary 
number/mm2 (Figure 12b). 
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Figure 12. Mean capillary area (µm2) and capillary density (capillaries/mm2) in rabbit skeletal muscles  six days 
after the GT. From original publications I and III and unpublished data. 
 
VEGFR-2 is known to mediate angiogenic effects. AdVEGF-A165 is a potent 
inducer of angiogenesis increasing mean capillary size 6-fold as compared to AdLacZ.  
Surprisingly, AdVEGF-D∆N∆C was even more potent angiogenic factor. Proteolytic 
processing increases the affinity of VEGF-D to VEGFR-2 by 17,000 fold (McColl et al., 
2007), thus potentiating its angiogenic effects. AdVEGF-Cfull and AdVEGF-Dfull failed to 
induce angiogenesis, indicating that they were not proteolytically processed in this model. 
The lack of proteolytic processing may be due to species-specific differences as human 
growth factors were used in rabbit skeletal muscles, or due to non-inflammatory 
environment lacking proteases such as active plasmin to activate these growth factors 
(McColl et al., 2003). Although rabbit VEGF-D is 88% identical to human VEGF-D 
(http://www.ensembl.org), species-specific functions are possible since binding profiles 
have been shown in mouse with similar gene sequence homology (84%) (Baldwin et al., 
2001). 
The differences in angiogenic potencies of AdVEGF-A and AdVEGF-D∆N∆C may be 
explained by their differential binding to extracellular matrix. VEGF-A165 binds to heparin 
sulphate proteoglycans on cell surfaces and is thus sequestered by the matrix in the 
vicinity of the transduced cells (Tammela et al., 2005a). AdVEGF-D∆N∆C on the other hand 
is freely soluble, and is distributed more widely into the muscle (Achen et al., 1998). 
AdVEGF-D∆N∆C may therefore be more readily available for VEGFR-2 on the endothelium. 
Capillary number is often used as an end point measurement in angiogenesis 
studies. Although mean capillary area was significantly increased, only AdVEGF-A 
significantly increased mean capillary number / myocyte. In previous studies, increase in 
mean capillary area has led to significant increases in tissue perfusion indicating that 
increase in capillary size alone is sufficient to increase perfusion in large animal models 
(Rissanen et al., 2005). Angiogenic mechanisms may vary between species. Increase in 
capillary density has been observed also in our laboratory in mouse skeletal muscles after 
adenoviral VEGF-A and VEGF-D∆N∆C GT (Kholova et al., 2007), while the same vectors 
only induce capillary enlargement in rabbit and pig skeletal muscles (Rissanen et al., 
2003a) and unpublished observations (Lähteenvuo et al. 2006). Expression time may also 
affect the quality of the angiogenic response observed. Adenoviral GT produces a rapid 
but transient expression of the therapeutic genes. Capillaries run parallel to myocytes in 
skeletal muscles, and tight structure of the tissue possibly limits the sprouting of new 
vessels. Capillaries were large but relatively regular in shape within the muscle bundles 
after AdVEGF-A GT (Figure 13a). Denser, more disorganized vessel structures were 
observed in connective tissue surrounding the skeletal muscles six days after the 
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AdVEGF-A GT supporting this hypothesis (Figure 13b). Flow has also been shown to 
regulate vessel architecture in AdVEGF-A transduced muscles (Rissanen et al., 2005). In 
our model arterial flow to transduced muscles was not disturbed, possibly explaining the 
lack of sprouting angiogenesis. 
 
 
VEGFR-2 stimulation induces blood vessel growth in ischemic skeletal muscle 
 
PlGF has been proposed to have a specialized function in ischemic tissues 
(Carmeliet, 2003) and VEGF-B has been shown to induce angiogenesis in ischemic 
hindlimbs (Silvestre et al., 2003), possibly due to VEGF-B/VEGF-A heterodimer formation 
(Yoon and Losordo, 2003). The function of VEGFR-1 ligands was therefore further studied 
in ischemic skeletal muscles. Endogenous angiogenesis was observed in the border of 
ischemic necrosis in AdLacZ transduced ischemic skeletal muscles (a). The angiogenic 
responses were in line with our results observed in normoxic skeletal muscles. Both 
AdVEGF-A (b) and PlGF (c) increased blood vessel growth. AdVEGF-B167 (d) and 
AdVEGF-B186 (e) did not induce angiogenesis in the ischemic skeletal muscles (Figure 14). 
 
Figure 14. Ischemic rabbit skeletal muscles 6 days after GT. CD31 staining (brown) for endothelial cells, 
magnification 100X, scale bar 200µm. From original publication III. 
 
 VEGF-B is expressed in skeletal muscles (Olofsson et al., 1996a), but is not 
required for skeletal muscle development as VEGF-B null mice develop normal peripheral 
musculature (Aase et al., 2001) suggesting a restricted role in the adult. In contrast to 
previous findings (Silvestre et al., 2003), AdVEGF-B did not increase angiogenesis in the 
transduced skeletal muscles. This is surprising, as adenoviral gene transfer produces high 
local protein levels. Differences in angiogenic response may therefore be due to different 
animal models and differences in end point measurements. However, other effects for 
VEGF-B such as metabolic and functional effects cannot be ruled out based on this study. 
VEGFR-1 and VEGFR-2 ligands induce blood vessel growth in normoxic 
myocardium 
  
Blood vessel growth in normoxic myocardium was studied 6 days after the GT 
(Figure 15). Capillaries were normal in AdLacZ transduced muscle samples (a). VEGFR-2 
ligands AdVEGF-A (e), AdVEGF-D∆N∆C (f) and AdVEGF-E (g) induced capillary growth 6 
days after the GT. In contrast to results in skeletal muscles, all VEGFR-1 ligands AdPlGF 
Figure 13. Capillary growth and 
glomerulus formation in rabbit skeletal 
muscles, AdVEGF-A transduced 
muscles six days after the GT. CD31 
staining (brown) for ECs, magnification 
200X, scale bar 100µm. Lähteenvuo et 
al., unpublished result. 
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(b), AdVEGF-B167 (c) and AdVEGF-B186 (d) induced angiogenesis in the myocardium. 
VEGFR-3 ligand AdVEGF-C156S induced only weak vessel enlargement (h). 
 
Figure 15. Transduced pig myocardium 6 days after the GT. Pecam-1 staining (brown) for ECs, magnification 
200X, scale bar 100µm. From original publication III and unpublished results, figure h Kattainen E et al. 
unpublished result 2009.  
 
VEGFR-1 and VEGFR-2 ligands induce angiogenesis in ischemic myocardium 
  
 Blood vessel growth was studied in the infarction scar edge six days after the GT 
(Figure 16). In AdLacZ transduced hearts, endogenous angiogenesis was observed both 
in the outer rim of the fibrotic scar (*) and weak capillary enlargement in the surrounding 
myocardium (a). AdVEGF-A (b), AdPlGF (c) and both AdVEGF-B167 (d) and AdVEGF-B186 
(e) induced angiogenesis. AdVEGF-B186 was the most potent angiogenic factor increasing 
the total vessel area by 2.9-fold as compared to AdLacZ (Figure 17) 
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Figure 16. Transduced pig myocardium from the border zone of a myocardial infarction scar 6 days after 
the GT. Pecam-1 staining (brown) for endothelial cells, magnification 100X, scale bar 200µm. From original 
publication III. 
 
 
Figure 17. Total vessel area (µm2) in  the infarction border zone 6 days after the GT. From original publication III. 
 
 The most potent angiogenic factors were chosen for the studies in ischemic 
myocardium. While the angiogenic effect of VEGF-B186 was weaker than that of AdVEGF-
A in normoxic muscle, it was the most efficient growth factor in the infarction edge. This 
may be due to differences in receptor signaling. VEGFR-1 is up-regulated in the ischemic 
myocardium (Marti and Risau, 1998). While VEGFR-1 has been shown to be a negative 
regulator of VEGF-A (Shibuya, 2006), it may be required for the angiogenic function of 
VEGF-B. If such an endogenous amplification mechanism of VEGF-B exists, it may 
increase the therapeutic potential of AdVEGF-B186 and further target the angiogenic 
response to ischemic area.  
Angiogenic effect persists in the ischemic tissue 
  
The angiogenic effect of AdVEGFA was studied on days 6 and 21 after the GT in 
normoxic and ischemic myocardium (Figure 18). The angiogenic effect was stronger in the 
ischemic myocardium (c) although the viral dose was one half of the dose used in the 
normoxic myocardium (a). Whereas blood vessel size had returned to baseline in the 
normoxic heart on day 21 (b), in the ischemic hearts angiogenic response persisted on 
day 21 (d). AdLacZ did not induce blood vessel growth in the normoxic myocardium on 
day 6 (e) or day 21 (f), and only mild capillary enlargement was seen in the ischemic heart 
on day 6 (g). The effect had returned almost to baseline by day 21 (h).  
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Figure 18. Normoxic (a-b, e-f) and ischemic (c-d, g-h) pig myocardium 6 (a,c,e,g) or 21 (b,d,f,h) days after 
the GT. Pecam-1 staining (brown) for ECs, magnification 200X, scale bar 100µm. From online data supplement 
of original publication III and unpublished results. 
 
 Angiogenic response in the ischemic myocardium was markedly stronger than in 
the normoxic myocardium. This is likely due to endogenous growth factor and receptor up-
regulation by hypoxia. VEGF-A binds to VEGFR-1 and VEGFR-2. VEGFR-1 has been 
shown to be directly up-regulated by hypoxia (Gerber et al., 1997; Marti and Risau, 1998), 
while VEGFR-2 up-regulation has been only demonstrated in vivo and occurs likely 
indirectly due to VEGF-A expression or by post-transcriptional mechanisms (Waltenberger 
et al., 1996). 
 Vessels persist in the ischemic tissue due to metabolic need. While in normoxic 
tissues new vessels or increased perfusion are not needed, in ischemic environment 
metabolic regulatory mechanisms maintain high perfusion in the enlarged vessels and the 
vessels do not regress when the growth factor production ceases. Hypoxia and 
accumulation of metabolites induce relaxation of arterioles, leading to increased blood flow 
(Guyton and Hall, 2000). This promotes vessel maturation by increasing smooth muscle 
coverage (Van Gieson et al., 2003). 
  
Angiogenesis is accompanied by arteriogenesis in ischemic myocardium 
  
 Ex vivo angiographies were performed six days after the gene transfer to visualize 
the formation of collateral vessels (Figure 19). Only a few arteries were visible in the 
infarction border zone in AdLacZ transduced hearts. AdVEGF-A and AdPlGF induced 
growth of collateral arteries above the infarction scar area. AdVEGF-B186 was the most 
potent inducer of collateral artery growth. A tree-like structure branching from the diagonal 
branches of LAD was observed in AdVEGF-B186 transduced hearts. 
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Figure 19. Ex vivo angiographies of the transduced pig hearts six days after the GT for visualization of collateral 
vessels. Infarction scar and border zone are circled, the arrows point to the occlusion site in the LAD. From 
original publication III. 
 
 Collateral arteries are required to supply blood flow to new capillaries in the 
infarction border zone. Although several studies have demonstrated collateral artery 
growth after growth factor administration, mechanisms governing arterial growth seem to 
be different from angiogenic mechanisms. Arteriogenesis is observed in normoxic tissue 
where no hypoxia-driven growth factor expression is observed (Rockstroh and Brown, 
2002). The effect of growth factor GT may therefore be indirect. Blood vessel area 
increases via growth of the vessel diameter by cell proliferation and vasodilation. This 
increases the pressure gradient between diagonal branches and capillary bed increasing 
flow and thus triggering arteriogenesis via increased shear stress. This has previously 
been demonstrated in rabbit hindlimb ischemia model after AdVEGF-A administration 
(Rissanen et al., 2005). 
 Induction of collateral growth indirectly by increasing flow up-stream from the 
angiogenic capillary bed may not be as straight forward in humans as in young, healthy 
animals. In the arteries of older patients atherosclerotic changes disturb blood flow and 
endothelial dysfunction may inhibit endogenous responses. Furthermore, dyslipidemia and 
hyperglycemia may attenuate vasodilation and recruitment of mononuclear cells essential 
for collateral growth (LeBlanc et al., 2008). 
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VEGF-B INDUCES MYOCARDIUM-SPECIFIC ANGIOGENESIS VIA A NOVEL 
ANGIOGENIC PAHWAY 
 
VEGF-B induced vessel growth is not dependent on nitric oxide production 
  
 
 
The role of NO is well established for the angiogenic function of VEGFR-2. 
Angiogenic effects of VEGF-A have been shown to be mediated via NO production 
(Fukumura et al., 2001) and NO has been shown to be a downstream signaling molecule 
in the VEGFR-2 signaling pathway. Also VEGFR-1 stimulation with PlGF has been shown 
to induce angiogenesis via NO production (Bussolati et al., 2001). However, these effects 
may have been indirect as the authors had previously shown that PlGF induces VEGFR-2 
phosphorylation  in fibroblasts and the effect of PlGF was inhibited by a VEGFR-2 
antibody (Khaliq et al., 1999). Although also anti-VEGF antibody inhibited these effects 
they were interpreted as indirect VEGFR-2 activation. Such cross-talk between VEGFR-1 
and VEGFR-2 has also been suggested by others (Autiero et al., 2003).  
NO production is an essential step in angiogenesis. NO induces vasodilation, 
increases blood flow and NO production also occurs in endogenous angiogenic 
processes. On the other hand NO increases vascular permeability and induces apoptosis 
in high concentrations. Lack of NO dependency in blood vessel growth is a new finding 
and suggests the angiogenic effects of AdVEGF-B186 are mediated via a novel angiogenic 
pathway. 
 
AdPlGF induces angiogenesis via VEGF-A up-regulation but AdVEGF-B186 induced 
angiogenesis is not dependent on a VEGFR-2 ligand 
 
The differences in angiogenic responses of the two VEGFR-1 ligands, AdPlGF 
and AdVEGF-B were evaluated further. VEGF-A staining of transduced skeletal muscles 
showed that AdPlGF up-regulated VEGF-A expression while AdVEGF-B did not (Figure 
21). Only a few VEGF-A positive cells were observed in the vicinity of the needle track in 
AdLacZ transduced muscles (a). AdVEGF-A transduced skeletal muscles stained positive 
for VEGF-A (b). Strong VEGF-A staining was observed also in AdPlGF transduced 
samples (c), while in AdVEGF-B transduced samples VEGF-A positive cells were only 
observed in the needle track (d). 
Nitric oxide synthase 
inhibitor L-NAME was given p.o. to 
inhibit NO production. L-NAME 
blocked the capillary growth induced 
by AdVEGF-A and AdPlGF but did 
not inhibit AdVEGF-B167 or AdVEGF-
B186 induced angiogenesis (Figure 
20). 
 
Figure 20. Mean capillary areas (µm2) in 
transduced myocardium, GF=growth factor. 
From the online data supplement of original 
publication III. 
 
 64 
In the myocardium, only occasional weakly VEGF-A positive cells were seen in 
AdLacZ transduced hearts (e). AdVEGF-A transduced tissue was strongly VEGF-A 
positive (f) and VEGF-A up-regulation was seen in AdPlGF transduced myocardium (g). 
No VEGF-A expression was seen in AdVEGF-B186  transduced myocardium (h).  
 
Figure 21. Transduced rabbit skeletal muscles (a-d) and pig myocardium (d-g) six days after GT. VEGF-A 
staining (brown), magnification 200X, scale bar 100µm. Unpublished results. 
 
VEGF-A staining showed that AdPlGF up-regulates VEGF-A and the amount of 
VEGF-A staining was comparable to AdVEGF-A transduced samples. Several angiogenic 
growth factors have been shown to function via VEGF-A up-regulation (Deroanne et al., 
1997).  Interestingly, PlGF has previously been shown to up-regulate VEGFR-2 (Odorisio 
et al., 2002) and induce VEGFR-2 autophosphorylation (Autiero et al., 2003) although no 
direct binding to VEGFR-2 was observed. Previously, PlGF has been shown to induce 
VEGF-A secretion from human mononuclear cells (Bottomley et al., 2000).  A few VEGF-A 
positive cells were observed in the vicinity of the needle track in AdLacZ and AdVEGF-B 
transduced muscles. This may be due to endogenous VEGF-A production by the 
damaged cells in the needle track. 
The roles of VEGFR-1 and VEGFR-2 in PlGF-induced angiogenesis were further 
studied using adenoviruses encoding soluble VEGF-receptors (Figure 22). AdsVEGFR-1 
inhibited both AdVEGF-A and AdPlGF induced angiogenesis in skeletal muscles and 
AdVEGF-B186 induced angiogenesis in the myocardium (a and b). Also AdsVEGFR-2 
inhibited both AdVEGF-A and AdPlGF induced angiogenesis in the skeletal muscles (a) 
and AdVEGF-A induced angiogenesis in the myocardium, indicating that AdPlGF induced 
angiogenesis was dependent on a VEGFR-2 ligand. In contrast, AdVEGF-B186 induced 
angiogenesis in the myocardium was not blocked by AdsVEGFR-2 (b).  
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Figure 22. Mean capillary areas (µm2) in transduced rabbit skeletal muscles (a) and pig myocardium (b). In the 
legend – indicates growth factor alone. From original publication III. 
 
  Over-expression of soluble receptors was used to specify the roles of VEGFR-1 
and -2 on the angiogenic response of AdPlGF. Three-fold over-expression of the soluble 
receptors was used to ensure saturation of the receptor binding site on the growth factor. 
Both AdsVEGFR-1 and AdsVEGFR-2 inhibited the angiogenic effects of AdPlGF indicating 
that a VEGFR-2 ligand is required for the angiogenic function of PlGF. Soluble receptors 
are not optimal tools in receptor function experiments. The soluble receptor may inhibit 
interactions with other receptors and thus unspecifically inhibit the effect of the growth 
factor. An optimal approach would be a receptor inhibitor or a blocking antibody. The use 
of antibodies in large animal models is limited by the amount of antibody needed to reach 
sufficient local concentrations, and although several VEGFR antibodies are available their 
specificity to VEGFRs is limited (Kesisis et al., 2007). However, in our setting the 
limitations are smaller. Since PlGF does not bind to VEGFR-2, inhibitory effect of 
AdsVEGFR-2 indicates the presence of a VEGFR-2 ligand. 
The indirect mode of function was further supported by the notion that while 
VEGF-A is a potent inducer of vascular permeability in the Miles assay, PlGF homodimer 
did not induce vascular permeability in 30min while PlGF/VEGF heterodimer did induce a 
permeability response in higher concentrations (Lähteenvuo et al. unpublished results).  
 
AdVEGF-B induced angiogenesis is dependent on Nrp-1 
  
Several members of the VEGF family bind to neuropilin receptors. In AdLacZ 
transduced samples a low level of Nrp-1 staining was observed in cardiomyocytes and in 
ECs. In AdVEGF-A and AdPlGF transduced hearts angiogenic capillaries stained strongly 
positive for Nrp-1. In AdVEGF-B186 transduced samples both angiogenic capillaries and 
cardiomyocytes in the vicinity of the needle track stained positive for Nrp-1 (Figure 23). 
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Figure 23. Transduced pig skeletal muscle (a-d) and myocardium (e-l) six days after the GT. Nrp-1 staining 
(brown), magnification 200X, 100µm. From original publication III. 
 
Immunoprecipitation with Nrp-1 antibody and VEGF-B immunoblotting revealed 
that VEGF-B was bound to Nrp-1 (Figure 24 a). Some endogenous VEGF-B was also 
observed in the AdLacZ transduced samples (a). Recently, Nrp-1 was shown to mediate 
intracellular signaling. Activation of this signaling pathway was confirmed by binding of 
GIPC protein to Nrp-1 (b) and up-regulation of GAIP (c). Since GAIP was not bound to the 
signaling complex and was not immunoprecipitated with Nrp-1, the finding was confirmed 
by immunostaining of GAIP showing redistribution of GAIP in the cardiomyocytes (data not 
shown). 
 
Figure 24. Western blots. L=AdLacZ transduced tissue, B=AdVEGF-B186 transduced tissue, P=VEGF-B 
recombinant protein positive control. A) immunnoprecipitation with Nrp-1 antibody and detection with VEGF-B 
antibody. B) immunoprecipitation with Nrp-1 antibody and detection with GIPC antibody. C) detection with GAIP 
antibody.  
 
The role of Nrp-1 in myocardial angiogenesis was studied using an adenoviral 
construct expressing soluble Nrp-1 (Figure 25). AdsNrp-1 enhances the angiogenic effect 
of AdVEGF-A (Yamada et al., 2001). Possibly due to endogenous VEGF-A production in 
the ischemic tissue, AdsNrp-1 enhanced the angiogenic effect in AdLacZ transduced 
tissues (a vs. c). Also co-administration of AdsVEGFR-1 increased mean vessel size (b). 
In contrast, the angiogenic effect of VEGF-B186 was inhibited by AdsNrp-1 (d vs. e) and by 
AdsVEGFR-1 (f). Mean vessel sizes in the infarction border zone were quantified to 
confirm the result.  
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Figure 25. Trancduced pig myocardium 6 days after the GT, infarction border zone. Pecam-1 
staining,(brown) for ECs, magnification 100X, scale bar 200µm (a-f) and quantification of mean blood vessel area 
(µm2)(g). From original publication III. 
 
Nrp-1 has been shown to be expressed widely in different tissues, and in adults 
mainly in the arterial endothelium. Here we show that Nrp-1 is also expressed on 
cardiomyocytes and that Nrp-1 expression is up-regulated after VEGF-B GT. Neuropilins 
have been thought to function as co-receptors for VEGFRs, but recently an intracellular 
signaling pathway essential for blood vessel development was published (Wang et al., 
2006). Our results indicate that Nrp-1 is essential for VEGF-B mediated effects in the 
myocardium, but whether it acts independently or whether it modulates VEGFR function 
remains to be elucidated. Neuropilins have been shown to function in a ligand-dependent 
manner. Co-administration of AdsNrp-1 increased endogenous angiogenesis in AdLacZ 
transduced myocardium but blocked the vessel growth induced by AdVEGF-B186.  
 
FUNCTIONAL EFFECTS OF GENE TRANSFER 
Angiogenesis increases perfusion in skeletal muscle and myocardium 
 
 Perfusion was measured using fluorescent microsphere particles. Angiogenic 
factors increased perfusion both in the skeletal muscle and myocardium (Figure 26). In 
skeletal muscles, AdVEGF-A and AdVEGF-D∆N∆C were the most potent angiogenic factors 
inducing 4- and 3-fold increases in perfusion ratios, respectively (a), while in the 
myocardium AdVEGF-A and AdVEGF-B186 had the strongest effect on perfusion in the 
infarction border zone (b). 
 
Figure 26. Microsphere perfusion ratios in rabbit skeletal muscle (a) and ischemic pig myocardium (b) as 
compared to healthy tissue. From original publications I and III and unpublished results. 
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 The microsphere method is the gold standard in perfusion measurement. 
Microsphere particles are 7µm in diameter and the measurement is based on the 
microspheres being trapped in the capillary vessels. Mean vessel area in AdVEGF-D∆N∆C 
transduced skeletal muscles was 210µm corresponding to diameter of approximately 
16µm, too large for the microsphere particles to be trapped in the vessels. In addition, the 
muscles were perfusion fixed and thus microsphere particles that were not tightly wedged 
to vessels may have been washed out. The microsphere method may therefore 
underestimate perfusion ratios. This was confirmed by ultrasound perfusion 
measurements, where perfusion was increased by 20-30-fold as compared to controls 
(data not shown). 
Angiogenesis increases ejection fraction in ischemic myocardium 
 
  
 
  
The standard measurement for ejection fraction requires a standardized ultrasound 
projection of the heart. Pig has very narrow intercostal spaces preventing the use of 
transthoracic US techniques, and thus measurements were performed from longitudinal 
projections by using intracardiac ultrasound imaging. GT of the angiogenic factors induced 
edema in the anterior wall of the left ventricle which may also have affected the EF 
measurements.  
VASCULAR PERMEABILITY 
 
 Vascular permeability was measured using modified Miles assay (Figure 28). All 
angiogenic growth factors increased vascular permeability. AdLacZ GT did not increase 
leakage of plasma proteins as compared to intact muscles, yielding a permeability ratio of 
1.1. Angiogenic factors AdVEGF-A165, AdPlGF, ADVEGF-D∆N∆C and AdVEGF-E increased 
vascular permeability in skeletal muscles while VEGFR-3 ligands AdVEGF-Cfull, AdVEGF-
C156S AdVEGF-Dfull did not increase leakage of plasma proteins. 
Ejection fraction was 
measured at baseline, after AMI and 
six days after the gene transfer (Figure 
27). Ejection fraction decreased 
equally in all groups after AMI. In 
AdLacZ and AdVEGF-B167 transduced 
animals only slight increase in ejection 
fraction was observed. In contrast, both 
AdVEGF-A and AdVEGF-B186 
recovered ejection fraction almost back 
to the baseline level within six days.  
 
Figure 27. Ejection fraction (%) at baseline, after 
AMI and 6 days after the GT. From original 
publication III.  
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Figure 28. Plasma protein leakage ratios in rabbit skeletal muscles as compared to intact tissue. From original 
publications I, III and unpublished results. 
 
Blood vessel leakage and tissue edema are among the main safety concerns in 
angiogenic gene therapy. Several reports have been published about growth factors and 
growth factor combinations with blood vessel growth without increase in the vascular 
permeability in mouse models (Luttun et al., 2002; Zheng et al., 2006). However, in our 
hands all angiogenic growth factors also increased plasma protein leakage. Growth factor 
expression had lasted for several days at the time of the analysis, and acute and chronic 
mechanisms of vascular permeability are likely to be activated. EC proliferation was seen 
in all groups, and detachment of ECs and intercellular leakage are likely inevitable in the 
process of blood vessel growth. 
 
LYMPHATIC VESSEL GROWTH 
 
VEGFR-3 ligands induce lymphatic vessel growth 
  
Lymphatic vessels were studied using LYVE-1 staining of the transduced tissues 
(Figure 29). In AdLacZ transduced tissues, lymphatic vessels were observed between the 
muscle bundles. One or two thin-walled, open lymphatic channels were seen around 
larger collecting veins (a). VEGFR-1 ligands AdVEGF-A and AdPlGF induced a mild 
lymphangiogenic response. Both size and number of lymphatic channels were increased 
in the transduction area. AdVEGF-B167 and AdVEGF-B186 did not induce lymphatic vessel 
growth. A simplified grouping according to receptor binding profile is presented. 
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Figure 29. Transduced rabbit skeletal muscles 6 days after the GT. LYVE-1 staining (brown) for lymphatic 
ECs, magnification 200X, scale bar 100µm. From original publication IV  and unpublished results.  
 
 AdVEGF-A has been reported to induce lymphangiogenesis (Nagy et al., 2002). 
Mild lymphangiogenic response studied by LYVE-1 immunostaining was observed in all 
groups where angiogenesis and increased vascular permeability was observed. 
Endogenous signals for lymphatic vessel growth are poorly known. Macrophages have 
been shown to secrete lymphangiogenic factors and to stimulate lymphatic vessel growth 
in the cornea (Watari et al., 2008). When lymphatic vessel formation was studied in the 
skin, lymphatic flow was shown to precede the formation of lymphatic channels. It was 
therefore hypothesized that edema itself was the stimulus for lymphatic vessel growth, not 
direct receptor stimulation by the growth factors. 
 Both full and truncated (∆N∆C) forms of VEGF-C and VEGF-D bind to both 
VEGFR-2 and VEGFR-3, possibly producing a mixed angiogenic and lymphangiogenic 
response. Receptor-specific effect can be more precisely evaluated by receptor-specific 
ligands. Previously, no lymphatic vessel growth was observed after VEGFR-2 ligand 
VEGF-E GT, but only dilation of lymphatic vessels was seen (Wirzenius et al., 2007). In 
our model, also VEGF-E induced an increase both in the lymphatic vessel size and 
number suggesting a VEGFR-2 initiated response. The lymphangiogenic response of 
VEGFR-3 specific ligand VEGF-C156S was comparable to that of VEGF-C and –D full 
isoforms, suggesting that proteolytic processing does not play a major role and that their 
functions are mainly mediated via VEGFR-3.  
 To further assess the role of edema in lymphangiogenesis AdVEGF-A and 
AdVEGF-Dfull GTs were done in to the distal end of the rabbit semimembranosus muscle. 
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AdVEGF-A induced a weak but significant increase in the total lymphatic vessel area / field 
of view. Lymphatic vessels were organized and had an open lumen. In the AdVEGF-Dfull 
GT area lymphatic response was more pronounced and the total lymphatic vessel area 
was increased by 18-fold as compared to AdLacZ.  
 
Endogenous angiogenesis is accompanied by lymphangiogenesis 
  
Endogenous angiogenesis and lymphangiogenesis were studied in AdLacZ 
transduced ischemic skeletal muscles (Figure 30). Endogenous angiogenesis was 
observed in ischemic muscles, and mean capillary area was increased by 4-fold as 
compared to normal muscles (e and f). Total lymphatic vessel area was increased by 3-
fold in ischemic skeletal muscles (b and c). Lymphatic vessel growth was observed in 
between the muscle bundles in normoxic muscles (a), but both between muscle bundles 
(arrowheads) and under the muscle fascia (insert) in the border zone of the necrotic 
muscle (b).  
 
Figure 30. Rabbit skeletal muscles 6 days after the GT, LYVE-1 staining (brown) for lymphatic endothelial 
cells (top row) and CD31 staining (brown) for ECs (2nd row), magnification 200X, scale bar 100µm. 
Quantifications for total lymphatic vessel area (µm2/field of view) (c) and mean capillary area (µm2) (d). From 
original publication IV. 
 
 Presence of endogenous lymphangiogenesis has been demonstrated in healing 
myocardial infarction scars (Ishikawa et al., 2007) and in skin wounds (Paavonen et al., 
2000). If vascular permeability is an inevitable side-effect of blood vessel growth it is 
natural that an endogenous response has developed to control the formation of tissue 
edema.  
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Lymphatic vessel growth is not dependent on nitric oxide production 
 
 
 
COMBINATION GENE TRARAPY TO REDUCE EDEMA INDUCED BY THERAPEUTIC 
ANGIOGENESIS 
  
 The side-effects of angiogenic AdVEGF-D∆N∆C GT were treated with co-
administration of lymphangiogenic AdVEGF-Dfull (Figure 32). Mean capillary area was 
comparable in AdVEGF-D∆N∆C and combination group (a). Mean lymphatic area was 
increased in combination group by 4-fold as compared to AdVEGF-D∆N∆C alone (a). 
Indeed, the amount of extravasated plasma proteins in the interstitial space had also 
decreased by 68% in the combination group as compared to AdVEGF-D∆N∆C alone (b).  
 
Figure 32. Total blood vessel area and total lymphatic vessel area (% of total area) (a) and permeability ratio (c) 
in rabbit skeletal muscles 6 days after the GT. From original publication IV. 
 
 Co-administration of a lymphangiogenic factor was used to stimulate lymphatic 
vessel growth and hence to increase clearance of plasma proteins from the interstitial 
space to alleviate edema. AdVEGF-D∆N∆C does induce lymphatic vessel growth, but not 
sufficiently to reduce edema. In combination gene therapy, blood to lymphatic vessel ratio 
was comparable to that observed in endogenous angiogenesis and lymphatic clearance of 
plasma proteins was sufficient to alleviate edema. 
 Growth of blood vessels requires detachment of ECs to allow proliferation and 
migration. Vascular permeability may therefore be an unavoidable side effect of blood 
vessel growth. Stimulation of lymphatic vessel growth does not prevent these necessary 
steps in blood vessel growth but reduces edema by clearing extravasated proteins from 
the insterstitial space reducing edema.  
Nitric oxide synthase 
inhibitor was used to study the 
effect of NO on lymphatic vessel 
growth (Figure 31). L-NAME did 
not inhibit the increase in total 
lymphatic vessel area induced by 
VEGFR-3 ligand AdVEGF-Dfull. 
 
Figure 31. Total lymphatic vessel area (% 
of total area) (%) in rabbit skeletal muscles 
6 days after the GT. From original 
publication I. 
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SAFETY 
Blood vessel growth 
 
 
The major concern in angiogenic gene therapy is unwanted blood vessel growth. 
Possible effects on blood vessels were assessed from AdVEGF-B186 transduced animals.  
No signs of angiogenesis were observed in any of the control tissues studied (Figure 33). 
Representative images from liver (a), spleen (b), lung (c), kidney (d) and ovary (e) are 
presented. 
 
Figure 33. Pecam-1 staining for endothelial cells in safety tissues of a pig 6 days after the intramyocardial GT of 
VEGF-B186, magnification 200X, scale bar 100µm. Unpublished results. 
 
In VEGF-B null mice all tissues excluding the heart are normal suggesting a 
tissue-specific role for VEGF-B (Bellomo et al., 2000; Aase et al., 2001). However, since 
VEGF-B is widely expressed and some tumors have been reported to secrete VEGF-B, 
systemic effects cannot be excluded in the adult. VEGF-B186 is a soluble protein, and is 
therefore likely transported to systemic circulation by the lymphatic vessels at least to 
some extent.  Lack of blood vessel growth supports the safety of VEGF-B186 as a 
therapeutic protein, but since the metabolic effects of VEGF-B are largely unknown, other 
systemic effects cannot be excluded. 
Vascular permeability 
 
Accumulation of pericardial effusion was studied by ultrasound imaging, and 
plasma protein leakage was visualized and quantified by i.v. administration of Evans blue 
dye. To study the effects of blood vessel distribution and morphology, blood vessels in the 
epicardial surface of the heart were studied (Figure 34). 
AdVEGF-A and AdPlGF increased plasma protein extravasation in the skeletal 
muscles (a, b), while in the myocardium also VEGF-B186 increased vascular permeability 
(a, c). Plasma protein extravasation led to accumulation of pericardial effusion after 
AdVEGF-A, AdPlGF and to lesser extent after AdVEGF-B186 GT. Differences in the 
amount of effusion may be explained by the pattern of blood vessel growth. AdVEGF-A 
induced growth of glomerular vessel structures on the epicardial surface, while the 
angiogenic effect of VEGF-B186 was more balanced and wide-spread.  
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Figure 34.  Plasma protein leakage and pericardial effusion. 1st column: photographs of transduced rabbit 
skeletal muscles. 2nd column: photographs of transduced pig hearts. 3rd column: ultrasound images of the 
transduced hearts, *=pericardial space. 4th column: Pecam-1 staining, magnification 100X, *=epicardium. Plasma 
protein extravasation ratios as compared to intact tissue in skeletal muslces (b) and transduced myocardium (c). 
Unpublished results. 
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Increased vascular permeability is the main side effect of blood vessel growth. 
Increased plasma protein leakage was observed after administration of all angiogenic 
factors. In skeletal muscles plasma protein leakage leads to edema possibly leading to 
compression of the blood vessels and decreased blood flow. In myocardium excess fluid 
in the interstitial space may accumulate in the pericardial space restricting heart function. 
The solubility of the growth factors affected the accumulation of pericardial effusion. 
VEGF-A secreted from the transduced cells binds to matrix heparin sulphate 
proteoglycans, and angiogenesis was localized close to transduced cells. As shown by 
transduction efficiency studies with AdLacZ, the pressure gradient across the myocardial 
wall pushes the virus towards the epicardium, and the transduction efficiency is highest on 
the epicardial third of the ventricular wall. Further, blood vessel growth is more aberrant in 
loose connective tissue compartments. High local concentration of VEGF-A led to 
formation of leaky glomerular structures. AdVEGF-B186 is more soluble, and blood vessel 
growth was mostly seen within the myocardium and no leaky glomerular structures were 
observed. Vascular permeability is a dose-limiting side effect, and both the dose and 
biological properties of the growth factor used and the site of GT have to be chosen 
carefully to avoid these potentially hazardous side effects. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Adenoviral angiogenic gene therapy in large animal models has proved to be an 
efficient tool to induce blood vessel growth. Angiogenic growth factors increased both 
tissue area covered by blood vessels and induced growth of angiographically visible 
collateral arteries. Most importantly, angiogenic gene therapy improved the function of the 
transduced tissue. Perfusion was increased both in skeletal muscle and myocardium and 
treatment of ischemic myocardium improved the ejection fraction. Large animal models 
enabled the use of clinically relevant delivery methods, end point measurements and 
evaluation of biodistribution and safety in a large mammal. 
Angiogenic and lymphangiogenic profiles of the VEGF-family growth factors help 
to choose a suitable gene for therapeutic applications (Table 8). Quantitative side by side 
evaluation of blood and lymphatic vessel growth effects in a large animal model sets 
perspective for experiments performed in different animal models and species. 
Experiments in tissue environments intended for the clinical use are essential. Local 
environment, availability of target cells, receptors and other growth factors modulate the 
therapeutic response. Ischemic tissue was shown to be more responsive to angiogenic 
growth factors, setting a new dose-response curve for ischemic tissues. 
 
Table 8. Angiogenic and lymphangiogenic responses in normoxic and ischemic skeletal muscle and 
myocardium. Number of original publication in parentheses, u=unpublished result Lähteenvuo J et al., u*= 
unpublished result Kattainen E et al., u** unpublished result Lähteenvuo MT et al., ND= not determined. 
 ANGIOGENESIS LYMPHANGIO-
GENESIS 
 normoxic ischemic normoxic 
Growth 
factor 
skeletal 
muscle 
myocardium skeletal 
muscle 
myocardium skeletal muscle 
AdVEGF-A +++ (I, 
III) 
+++ (II, III) +++ (III) +++ (III) + (IV) 
AdPlGF +++ 
(III) 
+++ (III) ++ (III) ++ (III) + (u) 
AdVEGF-
B167 
- (III) + (III) - (III) + (III) - (I) 
AdVEGF-
B186 
- (III) +++ (III) - (III) +++ (III) - (u) 
AdVEGF-E +++ (u) +++ (u) ND ND + (u) 
VEGF-D∆N∆C +++ (I) +++ (II) +++ (u) +++ (u**) ++ (I, IV) 
VEGF-Cfull - (I) ND ND ND +++ (I) 
VEGF-Dfull - (I) ND ND ND +++ (I, IV) 
VEGF-C156S - (I) - (u*) ND - (u*) +++ (I) 
 
 Evaluation of the two most potent VEGFR-2 ligands in pig myocardium provided a 
basis for experiments to treat myocardial ischemia. An optimal vector and dose were 
established, and the delivery method optimized to recognize and target the area of choice 
within the myocardial wall. Methods to quantify and monitor vascular permeability in the 
myocardium are valuable when doses and follow-up methods for clinical trials are chosen.  
Evaluation of different VEGFR-1 ligands in skeletal muscle and myocardium 
revealed a novel angiogenic pathway activated by AdVEGF-B selectively in the heart. 
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Growth factors have been shown to have different angiogenic and lymphangiogenic 
profiles in different tissue environments (Byzova et al., 2002), but no tissue-specific growth 
factors have been reported. Discovery of a tissue-selective function of VEGF-B provides a 
new promising tool for angiogenic gene therapy. Moreover, VEGF-B may also have 
beneficial effects on the myocardial metabolism possibly selectively protecting the 
cardiomyocytes from ischemia and inhibiting apoptosis. The role of this novel pathway in 
endogenous angiogenesis and arteriogenesis remains to be elucidated. Expression 
patterns of suggested components of this pathway are all available in the sites of blood 
vessel growth supporting this hypothesis. VEGFR-1 is diffusely up-regulated in ischemic 
myocardium (Marti and Risau, 1998). VEGF-B null mice have cardiac defects, and VEGF-
B expression during embryogenesis and early postnatal life co-localized with developing 
coronary vessels and sites of angiogenesis (Bellomo et al., 2000). Further, although not 
regulated by hypoxia, Nrp-1 is expressed in both myocardium and arterial endothelium.   
Metabolic changes observed after AdVEGF-B186 GT open a whole new area of 
VEGF research. Recent reports have supported the concept of VEGF as a metabolic 
regulator. Kärpänen et al. reported recently that VEGF-B over-expression alters cardiac 
lipid metabolism, and VEGF-B has been shown to induce expression of fatty acid 
transporters both in vitro and in vivo (Carolina Rosenlew and Ulf Eriksson, personal 
communication). 
 Efficient induction of lymphatic vessel growth was achieved by adenoviral delivery 
of VEGFR-3 ligands. Lymphatic vessel area in the transduced muscles was increased, 
and most importantly, lymphatic vessels were functional and induction of lymphatic vessel 
growth was able to alleviate edema induced by angiogenic gene therapy. Combination 
gene therapy with angiogenic growth factors could be used to induce blood vessel growth 
with less severe side effects. Lymphatic vessel growth is a part of a balanced endogenous 
healing process. Lymphatic vessels grow in healing wounds (Paavonen et al., 2000), 
myocardial infarction scars (Ishikawa et al., 2007) and as shown in this study, in ischemic 
skeletal muscles. Blood/lymphatic vessel ratios calculated from these endogenous growth 
processes may provide a tool to estimate the increase in lymphatic vessel area required to 
reduce edema induced by therapeutic angiogenesis.  
 Experiments in large animal models are the last step before clinical trials. While 
VEGF-A has been studied in humans for over a decade, growth factor-specific safety 
information is needed before the less-known members of the VEGF-family are studied in 
humans. Ligands binding to VEGFR-3 may have side effects connected to lymphatic 
vessel growth and VEGFR-1 ligands may have yet unknown metabolic functions. VEGFs 
are known to be involved in both the development and function of the kidneys, and anti-
VEGF drugs have been reported to affect kidney function (Chen and Ziyadeh, 2008; 
Gurevich and Perazella, 2009). Therefore, the effects on kidney function should be 
addressed. 
 In conclusion, this study provides new data on both efficacy and safety of VEGFs 
for clinical angiogenic gene therapy. The optimal therapeutic gene for each application can 
be chosen based on angiogenic and lymphangiogenic properties of the growth factor.  
AdVEGF-D∆N∆ was shown to be an efficient angiogenic factor both in skeletal muscle and 
myocardium. Importantly, AdVEGF-B186 induced myocardium- specific angiogenic 
pathway via Nrp-1 receptor may provide a safer tool for induction of blood vessel growth. 
The most important side effect of angiogenic gene therapy, increased vascular 
permeability was assessed, and lymphangiogenic gene therapy to reduce angiogenesis-
induced edema was introduced. 
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